

To: ccmo bilbi@ccmo.nl]
Cc: [REDACTED]@novartis.com]
From: 5.1.2.e
5.1.2.e
Sent: Thur 7-2-2019 11:58:14
Subject: NL61015.029.17 - CCNP520A2202J - Digital Submission of a Substantial Amendment for approval: Protocol Amendment version 02 dated 18-December -2018
Received: Thur 7-2-2019 11:58:30
[B3a CCNP520A2202J EudraCT Application Form_05Feb2019.pdf](#)
[B3b CCNP520A2202J EudraCT Application Form_05Feb2019.xml](#)
[B3c CCNP520A2202J EudraCT Validation Report_05Feb2019.pdf](#)
[B5 CCNP520A2202J Substantial Amendment Notification Form_07Feb2019.pdf](#)
[A1 CCNP520A2202J Cover Letter NL61015.029.17_07Feb2019.pdf](#)

Dear Madam/Sir,

On behalf of the Sponsor, Novartis Pharma AG, PAREXEL International Romania s.r.l. herewith submits a substantial amendment to the above referenced clinical trial for review and authorization.

The changes in this amendment relate to:

- ☐ the addition of a new IMP;
- ☐ a substantial change of the current IMP
- ☒ other, namely: **Protocol:** Clinical Trial Protocol Amendment 02 dated 18 December 2018

With this submission, we declare that all relevant documents of the present submission dossier are signed by the persons authorised for this task.

We trust that the information provided in the application is sufficient, however if you require any further information, please contact us.

Yours faithfully,

5.1.2.e on behalf of 5.1.2.e

5.1.2.e

Providing services for Novartis DRA

Tel.: +40.312 5.1.2.e

Fax: +40.372 5.1.2.e

E-mail: 5.1.2.e@novartis.com

PAREXEL International Romania

Metropolis Center, Str. Grigore Alexandrescu Nr. 89-97,
Bucharest, Romania, 010624

REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE COMMUNITY
--

To be filled in by the applicant

The questions in this form for the request for authorisation from the Competent Authority are also relevant for the opinion from an Ethics Committee (it represents module 1 of the form for applying to an ethics committee) and can be used as part of that application. Please indicate the relevant purpose in a box below.

REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY:
REQUEST FOR OPINION OF THE ETHICS COMMITTEE:

Yes ●

No ●

A. TRIAL IDENTIFICATION

A.1	Member State in which the submission is being made:	Netherlands - Competent Authority
A.2	EudraCT number:	2016-002976-28
A.3	Full title of the trial: English	A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)
A.3.1	Title of the trial for lay people, in easily understood, i.e. non-technical, language: English	To evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)
A.3.2	Name or abbreviated title of the trial where available:	
A.4	Sponsor's protocol code number, version and date ¹ :	
A.4.1	Sponsor's protocol code number:	CCNP520A2202J
A.4.2	Sponsor's protocol version:	v02
A.4.3	Sponsor's protocol date:	2018-12-18
A.5	Additional international study identifiers (e.g. WHO, ISRCTN ² , US NCT Number ³) if available	
A.5.1	ISRCTN number:	
A.5.2	US NCT number:	NCT03131453
A.5.3	WHO Universal Trial Number (UTN):	
A.5.4	Other Identifier:	
A.6	Is this a resubmission?	No ●
	If 'Yes', indicate the resubmission letter ⁴ :	First Submission
A.7	Is the trial part of an agreed Paediatric Investigation Plan?	No ●
A.8	EMA Decision number of Paediatric Investigation Plan:	

B. IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST

B.1	SPONSOR	
B.1.1	Name of organisation:	Novartis Pharma AG
B.1.2	Name of the person to contact:	
B.1.2.1	Given name	5.1.2.e
B.1.2.2	Middle name	
B.1.2.3	Family name	5.1.2.e
B.1.3	Address:	
B.1.3.1	Street address	Lichtstrasse 35
B.1.3.2	Town/city	Basel
B.1.3.3	Post code	CH-4056
B.1.3.4	Country	Switzerland
B.1.4	Telephone number:	+41 6 5.1.2.e
B.1.5	Fax number:	
B.1.6	E-mail:	5.1.2.e @novartis.com

B.2	LEGAL REPRESENTATIVE ⁵ OF THE SPONSOR IN THE COMMUNITY FOR THE PURPOSE OF THIS TRIAL (if different from the sponsor)	
B.2.1	Name of organisation:	Novartis Pharma Arzneimittel GmbH
B.2.2	Name of person to contact:	
B.2.2.1	Given name	5.1.2.e
B.2.2.2	Middle name	
B.2.2.3	Family name	5.1.2.e
B.2.3	Address:	
B.2.3.1	Street address	Roonstrasse 25
B.2.3.2	Town/city	Nürnberg
B.2.3.3	Post code	D-90429
B.2.3.4	Country	Germany
B.2.4	Telephone number:	+49 911 2731 5.1.2.e
B.2.5	Fax number:	+49 911 2731 5.1.2.e
B.2.6	E-mail:	5.1.2.e @novartis.com

B.3	STATUS OF THE SPONSOR:	
B.3.1	Commercial:	Yes •
B.3.2	Non commercial:	No •

B.4	Source(s) of Monetary or Material Support for the clinical trial (repeat as necessary):	
B.4.1	Name of organisation:	Novartis Pharma AG
B.4.2	Country:	Switzerland

B.5	Contact point ⁶ designated by the sponsor for further information on the trial	
B.5.1	Name of organisation:	Novartis Pharma AG
B.5.2	Functional name of contact point (e.g. "Clinical Trial Information Desk"):	Clinical Trial Information Desk
B.5.3	Address:	
B.5.3.1	Street address	Lichtstrasse 35
B.5.3.2	Town/city	Basel
B.5.3.3	Post code	CH-4056
B.5.3.4	Country	Switzerland
B.5.4	Telephone number:	+44 61 5.1.2.e
B.5.5	Fax number:	+44 61 5.1.2.e
B.5.6	E-mail: (use a functional e-mail address rather than a personal one)	5.1.2.e @novartis.com

C. APPLICANT IDENTIFICATION, (please tick the appropriate box)

C.1	REQUEST FOR THE COMPETENT AUTHORITY		
C.1.1	Sponsor		
C.1.2	Legal representative of the sponsor		
C.1.3	Person or organisation authorised by the sponsor to make the application Yes •		
C.1.4	Complete the details of the applicant below even if they are provided elsewhere on the form:		
C.1.4.1	Name of Organisation:	Parexel International Romania s.r.l.	
C.1.4.2	Name of contact person:		
C.1.4.2.1	Given name	5.1.2.e	
C.1.4.2.2	Middle name		
C.1.4.2.3	Family name	5.1.2.e	
C.1.4.3	Address:		
C.1.4.3.1	Street address	89-97 Grigore Alexandrescu St.	
C.1.4.3.2	Town/city	Bucharest	
C.1.4.3.3	Post code	010624	
C.1.4.3.4	Country	Romania	
C.1.4.4	Telephone number:	+40 31 5.1.2.e	
C.1.4.5	Fax number:	+40 37 5.1.2.e	
C.1.4.6	E-mail:	5.1.2.e @novartis.com	
C.1.5	Request to receive a copy of CTA data as XML:		
C.1.5.1	Do you want a copy of the CTA form data saved on EudraCT as an XML file	No •	
C.1.5.1.1	If Yes provide the e-mail address(es) to which it should be sent (up to 5 addresses):		
C.1.5.1.2	Do you want to receive this via password protected link(s)?	No •	
If you answer No to question C.1.5.1.2 the .xml file will be transmitted by less secure e-mail link(s)			

D. INFORMATION ON EACH IMP

Information on each 'bulk product' before trial-specific operations (blinding, trial specific packaging and labelling) should be provided in this section for each investigational medicinal product (IMP) being tested including each comparator and each placebo, if applicable. **For placebo go directly to D.8.** If the trial is performed with several products use extra pages and give each product a sequential number in D.1.1. If the product is a combination product, information should be given for each active substance.

D.1 IMP IDENTIFICATION		
Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial (assign numbers from 1-n):		
D.1.1	This refers to the IMP number:	PR1
D.1.2	IMP being tested	Yes •
D.1.3	IMP used as a comparator	No •

D.2 STATUS OF THE IMP		
D.2.1	Has the IMP to be used in the trial a marketing authorisation? No • If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.	
D.2.1.1	If 'Yes', specify the product to be used in the clinical trial:	
D.2.1.1.1	Trade name	
D.2.1.1.1.1	EV Product Code (where applicable)	
D.2.1.1.2	Name of the Marketing Authorisation Holder:	
D.2.1.1.3	Marketing Authorisation number (if Marketing Authorisation granted by a Member State):	
D.2.1.1.4	Is the IMP modified in relation to its Marketing Authorisation? Not Answered •	
D.2.1.1.4.1	If 'Yes', please specify:	
D.2.1.2	The country that granted the Marketing Authorisation	
D.2.1.2.1	Is this the Member State concerned with this application? No •	
D.2.2	Situations where an IMP to be used in the CT has a Marketing Authorisation in the Member State concerned, but the protocol allows that any brand of the IMP with a Marketing Authorisation in that Member State be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start	
D.2.2.1	In the protocol, is treatment defined only by active substance?	Not Answered •
D.2.2.1.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.2	In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS?	Not Answered •
D.2.2.2.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.3	The products to be administered as IMPs are defined as belonging to an ATC group ⁹	Not Answered •
D.2.2.3.1	If 'Yes', give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3	
D.2.2.4	Other:	Not Answered •
D.2.2.4.1	If 'Yes', please specify:	
D.2.3	IMPD submitted:	
D.2.3.1	Full IMPD:	Yes •
D.2.3.2	Simplified IMPD:	No •
D.2.3.3	Summary of product characteristics (SmPC) only:	No •
D.2.4	Has the use of the IMP been previously authorised in a	Yes •

D.2.4.1	clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States:	Belgium Finland France Germany Iceland Italy Netherlands Portugal Spain United Kingdom
D.2.5	Has the IMP been designated in this indication as an orphan drug in the Community?	No •
D.2.5.1	If 'Yes', give the orphan drug designation number ¹⁰ :	

D.2.6	Has the IMP been the subject of scientific advice related to this clinical trial?	Yes •
D.2.6.1	If 'Yes' to D.2.6, please indicate source of advice and provide a copy in the CTA request:	
D.2.6.1.1	CHMP ¹¹ ?	Yes •
D.2.6.1.2	National Competent Authority?	No •

D.3	DESCRIPTION OF THE IMP	
D.3.1	Product name where applicable ¹² :	CNP520 15 mg
D.3.2	Product code where applicable ¹³ :	CNP520
D.3.3	ATC codes, if officially registered ¹⁴ :	
D.3.4	Pharmaceutical form (use standard terms):	Capsule, hard
D.3.4.1	Is this a specific paediatric formulation?	No •
D.3.5	Maximum duration of treatment of a subject according to the protocol:	96 months
D.3.6	Dose allowed:	
D.3.6.1	For first trial only: Specify per day or total	Not Answered •
	Specify total dose (number and unit):	
	Route of administration (relevant to the first dose):	
D.3.6.2	For all trials Specify per day or total	Per day •
	Specify total dose (number and unit):	15 mg milligram(s)
	Route of administration (relevant to the maximum dose):	Oral use
D.3.7	Routes of administration (use standard terms):	Oral use

D.3.8	Name of each active substance (INN or proposed INN if available):	Not established
D.3.9	Other available name for each active substance (provide all available):	
D.3.9.1	CAS ¹⁵ number	
D.3.9.2	Current sponsor code	CNP520
D.3.9.3	Other descriptive name	
D.3.9.4	EV Substance code	SUB166276
D.3.9.5	Full Molecular formula	
D.3.9.6	Chemical/biological description of the Active Substance	
D.3.10	Strength (specify all strengths to be used):	
D.3.10.1	Concentration unit:	mg milligram(s)
D.3.10.2	Concentration type ("exact number", "range", "more than" or "up to"):	equal

D.3.10.3	Concentration (number).	15
----------	-------------------------	----

D.3.11	Type of IMP	
Does the IMP contain an active substance:		
D.3.11.1	Of chemical origin?	Yes ●
D.3.11.2	Of biological / biotechnological origin (other than Advanced Therapy IMP (ATIMP)?	No ●
Is this a:		
D.3.11.3	Advanced Therapy IMP (ATIMP)?	No ●
D.3.11.3.1	Somatic cell therapy medicinal product ¹⁶ ?	No ●
D.3.11.3.2	Gene therapy medicinal product ¹⁷ ?	No ●
D.3.11.3.3	Tissue Engineered Product ¹⁸ ?	No ●
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device ¹⁹)?	No ●
D.3.11.3.5	Has the Committee on Advanced Therapies issued a classification for this product?	No ●
D.3.11.3.5.1	If 'Yes' please provide that classification and its reference number:	
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy?	No ●
D.3.11.5	Radiopharmaceutical medicinal product?	No ●
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)?	No ●
D.3.11.7	Plasma derived medicinal product?	No ●
D.3.11.8	Extractive medicinal product?	No ●
D.3.11.9	Recombinant medicinal product?	No ●
D.3.11.10	Medicinal product containing genetically modified organisms?	No ●
D.3.11.10.1	Has the authorisation for contained use or release been granted?	No ●
D.3.11.10.2	Is it pending?	No ●
D.3.11.11	Herbal medicinal product?	No ●
D.3.11.12	Homeopathic medicinal product?	No ●
D.3.11.13	Another type of medicinal product?	No ●
D.3.11.13.1	If 'another type of medicinal product' specify the type of medicinal product:	
D.3.12	Mode of action (<i>free text</i> ²⁰) CNP520 is an orally active beta-secretase (BACE-1) inhibitor	
D.3.13	Is it an IMP to be used in a first-in-human clinical trial?	No ●
D.3.13.1	If 'Yes', are there risk factors identified, according to the guidance FIH ²¹	

D.4	SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)	
D.4.1	Origin of cells	
D.4.1.1	Autologous	No ●
D.4.1.2	Allogeneic	No ●
D.4.1.3	Xenogeneic	No ●
D.4.1.3.1	If 'Yes', specify the species of origin:	
D.4.2	Type of cells	
D.4.2.1	Stem cells	No ●
D.4.2.2	Differentiated cells	No ●
D.4.2.2.1	If 'Yes', specify the type (e.g. keratinocytes, fibroblasts, chondrocytes...):	
D.4.2.3	Others:	No ●
D.4.2.3.1	If others, specify:	
D.5	GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS	

D.5.1	Gene(s) of interest:	
D.5.2	In vivo gene therapy:	No ●
D.5.3	Ex vivo gene therapy:	No ●
D.5.4	Type of gene transfer product	
D.5.4.1	Nucleic acid (e.g. plasmid):	No ●
	If 'Yes', specify if:	
D.5.4.1.1	Naked:	No ●
D.5.4.1.2	Complexed	No ●
D.5.4.2	Viral vector:	No ●
D.5.4.2.1	If 'Yes', specify the type: adenovirus, retrovirus, AAV, ...:	
D.5.4.3	Others	No ●
D.5.4.3.1	If others, specify:	
D.5.5	Genetically modified somatic cells:	No ●
	If 'Yes', specify the origin of the cells:	
D.5.5.1	Autologous:	No ●
D.5.5.2	Allogeneic:	No ●
D.5.5.3	Xenogeneic:	No ●
D.5.5.3.1	If 'Yes', specify the species of origin:	
D.5.5.4	Specify type of cells (hematopoietic stem cells...):	

D.6 TISSUE ENGINEERED PRODUCT		
The indication which determines that this is a Tissue Engineered Product as opposed to a Cell Therapy product is given in section E.1.1.		
D.6.1	Origin of cells	
D.6.1.1	Autologous	No ●
D.6.1.2	Allogeneic	No ●
D.6.1.3	Xenogeneic	No ●
D.6.1.3.1	If 'Yes', specify the species of origin:	
D.6.2	Type of cells	
D.6.2.1	Stem cells	No ●
D.6.2.2	Differentiated cells	No ●
D.6.2.2.1	If 'Yes', specify the type of cells(e.g. keratinocytes, fibroblasts, chondrocytes, ...):	
D.6.2.3	Others:	No ●
D.6.2.3.1	If others, specify:	

D.7 PRODUCTS CONTAINING DEVICES (i.e. MEDICAL DEVICES, SCAFFOLDS ETC.)		
D.7.1	Give a brief description of the device:	
D.7.2	What is the name of the device?	
D.7.3	Is the device implantable?	No ●
D.7.4	Does this product contain:	
D.7.4.1	A medical device?	No ●
D.7.4.1.1	Does this medical device have a CE mark?	No ●
D.7.4.1.1.1	The notified body is:	
D.7.4.2	Bio-materials?	No ●
D.7.4.3	Scaffolds?	No ●
D.7.4.4	Matrices?	No ●
D.7.4.5	Other?	No ●
D.7.4.5.1	If other, specify:	

D.1 IMP IDENTIFICATION		
Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial (assign numbers from 1-n):		
D.1.1	This refers to the IMP number:	PR2
D.1.2	IMP being tested	Yes •
D.1.3	IMP used as a comparator	No •

D.2 STATUS OF THE IMP		
D.2.1	Has the IMP to be used in the trial a marketing authorisation? No • If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.	
D.2.1.1	If 'Yes', specify the product to be used in the clinical trial:	
D.2.1.1.1	Trade name	
D.2.1.1.1.1	EV Product Code (where applicable)	
D.2.1.1.2	Name of the Marketing Authorisation Holder:	
D.2.1.1.3	Marketing Authorisation number (if Marketing Authorisation granted by a Member State):	
D.2.1.1.4	Is the IMP modified in relation to its Marketing Authorisation? Not Answered •	
D.2.1.1.4.1	If 'Yes', please specify:	
D.2.1.2	The country that granted the Marketing Authorisation	
D.2.1.2.1	Is this the Member State concerned with this application? No •	
D.2.2	Situations where an IMP to be used in the CT has a Marketing Authorisation in the Member State concerned, but the protocol allows that any brand of the IMP with a Marketing Authorisation in that Member State be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start	
D.2.2.1	In the protocol, is treatment defined only by active substance?	Not Answered •
D.2.2.1.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.2	In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS?	Not Answered •
D.2.2.2.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.3	The products to be administered as IMPs are defined as belonging to an ATC group ⁹	Not Answered •
D.2.2.3.1	If 'Yes', give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3	
D.2.2.4	Other:	Not Answered •
D.2.2.4.1	If 'Yes', please specify:	
D.2.3	IMPD submitted:	
D.2.3.1	Full IMPD:	Yes •
D.2.3.2	Simplified IMPD:	No •
D.2.3.3	Summary of product characteristics (SmPC) only:	No •
D.2.4	Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? Yes •	
D.2.4.1	If 'Yes' specify which Member States:	Belgium Finland France Germany Iceland Italy Netherlands Portugal

		Spain	United Kingdom
D.2.5	Has the IMP been designated in this indication as an orphan drug in the Community?	No •	
D.2.5.1	If 'Yes', give the orphan drug designation number ¹⁰ :		
D.2.6	Has the IMP been the subject of scientific advice related to this clinical trial?	Yes •	
D.2.6.1	If 'Yes' to D.2.6, please indicate source of advice and provide a copy in the CTA request:		
D.2.6.1.1	CHMP ¹¹ ?	Yes •	
D.2.6.1.2	National Competent Authority?	No •	
D.3	DESCRIPTION OF THE IMP		
D.3.1	Product name where applicable ¹² :	CNP520 50 mg	
D.3.2	Product code where applicable ¹³ :	CNP520	
D.3.3	ATC codes, if officially registered ¹⁴ :		
D.3.4	Pharmaceutical form (use standard terms):	Capsule, hard	
D.3.4.1	Is this a specific paediatric formulation?	No •	
D.3.5	Maximum duration of treatment of a subject according to the protocol:	96 months	
D.3.6	Dose allowed:		
D.3.6.1	For first trial only: Specify per day or total Specify total dose (number and unit): Route of administration (relevant to the first dose):	Not Answered •	
D.3.6.2	For all trials Specify per day or total Specify total dose (number and unit): Route of administration (relevant to the maximum dose):	Per day • 50 mg milligram(s) Oral use	
D.3.7	Routes of administration (use standard terms):	Oral use	
D.3.8	Name of each active substance (INN or proposed INN if available):	Not established	
D.3.9	Other available name for each active substance (provide all available):		
D.3.9.1	CAS ¹⁵ number		
D.3.9.2	Current sponsor code	CNP520	
D.3.9.3	Other descriptive name		
D.3.9.4	EV Substance code	SUB166276	
D.3.9.5	Full Molecular formula		
D.3.9.6	Chemical/biological description of the Active Substance		
D.3.10	Strength (specify all strengths to be used):		
D.3.10.1	Concentration unit:	mg milligram(s)	
D.3.10.2	Concentration type ("exact number", "range", "more than" or "up to"):	equal	
D.3.10.3	Concentration (number).	50	
D.3.11	Type of IMP		
Does the IMP contain an active substance:			
D.3.11.1	Of chemical origin?	Yes •	
D.3.11.2	Of biological / biotechnological origin (other than Advanced Therapy IMP (ATIMP))?	No •	
Is this a:			
D.3.11.3	Advanced Therapy IMP (ATIMP)?	No •	

D.3.11.3.1	Somatic cell therapy medicinal product ¹⁶ ?	No ●
D.3.11.3.2	Gene therapy medicinal product ¹⁷ ?	No ●
D.3.11.3.3	Tissue Engineered Product ¹⁸ ?	No ●
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device ¹⁹)?	No ●
D.3.11.3.5	Has the Committee on Advanced Therapies issued a classification for this product?	No ●
D.3.11.3.5.1	If 'Yes' please provide that classification and its reference number:	
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy?	No ●
D.3.11.5	Radiopharmaceutical medicinal product?	No ●
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)?	No ●
D.3.11.7	Plasma derived medicinal product?	No ●
D.3.11.8	Extractive medicinal product?	No ●
D.3.11.9	Recombinant medicinal product?	No ●
D.3.11.10	Medicinal product containing genetically modified organisms?	No ●
D.3.11.10.1	Has the authorisation for contained use or release been granted?	No ●
D.3.11.10.2	Is it pending?	No ●
D.3.11.11	Herbal medicinal product?	No ●
D.3.11.12	Homeopathic medicinal product?	No ●
D.3.11.13	Another type of medicinal product?	No ●
D.3.11.13.1	If 'another type of medicinal product' specify the type of medicinal product:	
D.3.12	Mode of action (<i>free text</i> ²⁰) CNP520 is an orally active beta-secretase (BACE-1) inhibitor	
D.3.13	Is it an IMP to be used in a first-in-human clinical trial?	No ●
D.3.13.1	If 'Yes', are there risk factors identified, according to the guidance FIH ²¹	

D.4 SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)		
D.4.1	Origin of cells	
D.4.1.1	Autologous	No ●
D.4.1.2	Allogeneic	No ●
D.4.1.3	Xenogeneic	No ●
D.4.1.3.1	If 'Yes', specify the species of origin:	
D.4.2	Type of cells	
D.4.2.1	Stem cells	No ●
D.4.2.2	Differentiated cells	No ●
D.4.2.2.1	If 'Yes', specify the type (e.g. keratinocytes, fibroblasts, chondrocytes...):	
D.4.2.3	Others:	No ●
D.4.2.3.1	If others, specify:	

D.5 GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS		
D.5.1	Gene(s) of interest:	
D.5.2	In vivo gene therapy:	No ●
D.5.3	Ex vivo gene therapy:	No ●
D.5.4	Type of gene transfer product	
D.5.4.1	Nucleic acid (e.g. plasmid):	No ●
	If 'Yes', specify if:	
D.5.4.1.1	Naked:	No ●
D.5.4.1.2	Complexed	No ●
D.5.4.2	Viral vector:	No ●
D.5.4.2.1	If 'Yes', specify the type: adenovirus, retrovirus, AAV, ...:	

D.5.4.3	Others	No ●
D.5.4.3.1	If others, specify:	
D.5.5	Genetically modified somatic cells: If 'Yes', specify the origin of the cells:	No ●
D.5.5.1	Autologous:	No ●
D.5.5.2	Allogeneic:	No ●
D.5.5.3	Xenogeneic:	No ●
D.5.5.3.1	If 'Yes', specify the species of origin:	
D.5.5.4	Specify type of cells (hematopoietic stem cells...):	

D.6 TISSUE ENGINEERED PRODUCT The indication which determines that this is a Tissue Engineered Product as opposed to a Cell Therapy product is given in section E.1.1.		
D.6.1	Origin of cells	
D.6.1.1	Autologous	No ●
D.6.1.2	Allogeneic	No ●
D.6.1.3	Xenogeneic	No ●
D.6.1.3.1	If 'Yes', specify the species of origin:	
D.6.2	Type of cells	
D.6.2.1	Stem cells	No ●
D.6.2.2	Differentiated cells	No ●
D.6.2.2.1	If 'Yes', specify the type of cells(e.g. keratinocytes, fibroblasts, chondrocytes, ...):	
D.6.2.3	Others:	No ●
D.6.2.3.1	If others, specify:	

D.7 PRODUCTS CONTAINING DEVICES (i.e. MEDICAL DEVICES, SCAFFOLDS ETC.)		
D.7.1	Give a brief description of the device:	
D.7.2	What is the name of the device?	
D.7.3	Is the device implantable?	No ●
D.7.4	Does this product contain:	
D.7.4.1	A medical device?	No ●
D.7.4.1.1	Does this medical device have a CE mark?	No ●
D.7.4.1.1.1	The notified body is:	
D.7.4.2	Bio-materials?	No ●
D.7.4.3	Scaffolds?	No ●
D.7.4.4	Matrices?	No ●
D.7.4.5	Other?	No ●
D.7.4.5.1	If other, specify:	

D.8 INFORMATION ON PLACEBO (if relevant; repeat as necessary)

D.8.1	Is there a placebo:	Yes ●
D.8.2	This refers to placebo number:	PL1
D.8.3	Pharmaceutical form:	Capsule, hard
D.8.4	Route of administration:	Oral use
D.8.5	Which IMP is it a placebo for? Specify IMP Number(s) from D.1.1	PR1

D.8.5.1	Composition, apart from the active substance(s):	
D.8.5.2	Is it otherwise identical to the IMPy	No •
D.8.5.2.1	If not, specify major ingredients:	
	5.1.1.c	
D.8.5	Which IMP is it a placebo for? Specify IMP Number(s) from D.1.1	PR2
D.8.5.1	Composition, apart from the active substance(s):	
D.8.5.2	Is it otherwise identical to the IMPy	No •
D.8.5.2.1	If not, specify major ingredients:	
	5.1.1.c	

D.9 SITE(S) WHERE THE QUALIFIED PERSON CERTIFIES BATCH RELEASE

22

This section is dedicated to **finished** IMPs, i.e. medicinal products randomised, packaged, labelled and certified for use in the clinical trial. If there is more than one site or more than one IMP is certified, use extra pages and give each IMP its number from section D.1.1 or D.8.2. In the case of multiple sites indicate the product certified by each site.

D.9.1	Do not fill in section D.9.2 for an IMP that: Has a MA in the EU and Is sourced from the EU market and Is used in the trial without modification(e.g. not overencapsulated) and The packaging and labelling is carried out for local use only as per article 9.2. of the Directive 2005/28/EC (GCP Directive) If all these conditions are met tick • and list the number(s) of each IMP including placebo from sections D.1.1 and D.8.2 to which this applies
-------	--

D.9.2	Who is responsible in the Community for the certification of the finished IMPs?	
	This site is responsible for certification of (list the number(s) of each IMP including placebo from sections D.1.1 and D.8.2):	PR1 PR2
		PL1
	please tick the appropriate box:	
D.9.2.1	Manufacturer	Yes •
D.9.2.2	Importer	Yes •
D.9.2.3	Name of the organisation:	Novartis Pharma Arzneimittel GmbH
D.9.2.4	Address:	
D.9.2.4.1	Street Address	Roonstrasse 25
D.9.2.4.2	Town/City	Nürnberg
D.9.2.4.3	Post Code	D-90429
D.9.2.4.4	Country	Germany
D.9.2.5	Give the manufacturing authorisation number:	5.1.1.c
D.9.2.5.1	If No authorisation, give the reasons:	
Where the product does not have a MA in the EU, but is supplied in bulk and final packaging and labelling for local use is carried out in accordance with article 9.2 of Directive 2005/28/EC (GCP Directive) then enter the site where the product was finally certified for release by the Qualified Person for use in the clinical trial at D.9.2 above.		

E. GENERAL INFORMATION ON THE TRIAL

This section should be used to provide information about the aims, scope and design of the trial. When the protocol includes a sub-study in the MS concerned section E.2.3 should be completed providing information about the sub-study. To identify it check the sub-study box in the 'Objective of the trial' question below.

E.1	MEDICAL CONDITION OR DISEASE UNDER INVESTIGATION				
E.1.1	Specify the medical condition(s) to be investigated ²³ (free text): English Alzheimer's disease				
E.1.1.1	Medical condition in easily understood language English Dementia				
E.1.1.2	Therapeutic area Diseases [C] - Nervous System Diseases [C10]				
E.1.2	MedDRA version, system organ class, level, term and classification code ²⁴ :				
	Version	System Organ Class	Classification Code	Term	Level
	20.0	100000004852	10001896	Alzheimer's disease	LLT
E.1.3	Is any of the conditions being studied a rare disease ²⁵ ? No •				
E.2	OBJECTIVE OF THE TRIAL				
E.2.1	Main objective: English - To demonstrate the effect of CNP520 vs placebo on time to diagnosis of MCI due to AD or dementia due to AD, whichever occurs first during the course of the study. - To demonstrate the effect of CNP520 vs placebo on cognition using APCC.				
E.2.2	Secondary objectives: English Key secondary objective: - To demonstrate the effects of CNP520 vs placebo on global clinical status. Secondary objectives: - To demonstrate the safety and tolerability of CNP520 vs placebo. - To demonstrate the effects of CNP520 vs placebo on cognition using Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). - To demonstrate the effects of CNP520 vs placebo on function. - To demonstrate the effects of CNP520 vs placebo on Magnetic Resonance Imaging (MRI) measures suggestive of cerebral amyloid angiopathy (CAA). - To demonstrate the effects of CNP520 vs placebo on brain atrophy. - To demonstrate the effects of CNP520 vs placebo on AD-related biomarkers.				
E.2.3	Is there a sub-study? No •				
E.2.3.1	If 'Yes', give the full title, date and version of each sub-study and their related objectives:				
E.3	PRINCIPAL INCLUSION CRITERIA (list the most important)				
	English	Screening part I: Participants eligible for inclusion must fulfill all of the following criteria prior to scheduling the genetic disclosure. 1. Written informed consent must be obtained before any assessment is performed as part of the study, including consent to receive disclosure of their risk estimates to develop clinical symptoms of AD based on their APOE genotype and, if HTs, with evidence of elevated brain amyloid. 2. Male or female, age 60-75 years inclusive, at the time of signing the informed consent. To ensure that no more than 20% of participants in			

the age group 60-64 years are randomized across the whole recruitment period, a site level process will be implemented.

3. Females must be considered post-menopausal and not of child bearing potential i.e. they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. history of vasomotor symptoms), or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation.

4. Intellectually, visually and auditorily capable, fluent in, and able to read, the language in which study assessments are administered (e.g. completion of at least 6 years of regular schooling or sustained employment or equivalent local level of knowledge).

5. Mini-Mental State Examination total score ≥ 24 .

6. Willing to have a study partner throughout the study.

Screening part II: Participants eligible for inclusion must fulfill all of the following criteria prior to randomization based on the results from the screening test procedures.

7. Carrier of at least one $\epsilon 4$ allele of the APOE gene: HMs with elevated or not elevated brain amyloid OR HTs with elevated brain amyloid (as measured in CSF collected via lumbar puncture or by amyloid PET imaging).

Note: In cases where both lumbar puncture (CSF) amyloid and amyloid PET imaging tests are performed, at least one should be indicative of elevated brain amyloid.

8. Cognitively unimpaired at screening visit as defined by: Score of 85 or greater on the RBANS delayed memory index score AND CDR global score of 0 with two special exceptions: a) If the RBANS delayed memory index score is between 70 and 84 (inclusive) AND the global CDR = 0, the participant may be allowed to continue ONLY if the investigator judges that cognition is unimpaired following review of the MCI/dementia criteria; b) If the global CDR score = 0.5 AND the RBANS delayed memory index score is 85 or greater, the participant may be allowed to continue ONLY if the investigator judges that cognition is unimpaired following review of the MCI/dementia criteria.

9. Having a study partner who agrees to participate in the study and who is intellectually, visually, and auditorily capable, and fluent in, and able to read, the language in which study assessments are administered. Additionally, the study partner must be capable of and willing to: a) Accompany the participant to visits that requires the input of the study partner; b) Meet the definition of a "study partner".

Other protocol defined inclusion criteria may apply.

E.4	PRINCIPAL EXCLUSION CRITERIA (list the most important)
English	Screening part I: Participants will be excluded if they fulfill any of the following criteria prior to scheduling the genetic disclosure. 1. Current medical or neurological condition that might impact cognition or performance on cognitive assessments e.g. MCI, dementia, Huntington's or Parkinson's disease etc. 2. Advanced, severe progressive or unstable disease that may interfere with the safety, tolerability and study assessments, or put the participant at special risk e.g. active hepatitis, HIV infection, severe renal impairment, severe hepatic impairment etc. 3. History of malignancy of any organ system, treated or untreated, within the past 60 months, regardless of whether there is evidence of local recurrence or metastases. However, localized nonmalignant tumors not requiring systemic chemo- or radio-therapy, localized basal or squamous cell carcinoma of the skin, in-situ cervical cancer are permitted. 4. Current treatment with Cholinesterase Inhibitors and/or another AD treatment.

5. Clinically relevant depigmenting or hypopigmenting conditions or active/history of chronic urticaria in the past year.
 6. Score "yes" on item 4 or 5 of the Suicidal Ideation section of the eCSSRS patient-reported outcome, if this ideation occurred in the past 6 months, or "yes" on any item of the Suicidal Behavior section, except for the "Non-Suicidal Self-Injurious Behavior", if this behavior occurred in the past 2 years prior to screening.
 7. Lacking psychological readiness to receive APOE genotype/amyloid status results, as assessed based on investigator's judgement supported by the pre-disclosure rating scales: Geriatric Depression Scale total score >6; Six Item Subset Inventory of the modified State Trait Anxiety Inventory total score >17.
 8. Use of other investigational drugs prior to screening until: Small molecules: after 5 half-lives, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; Biologicals: blood concentration has returned to baseline (or below serological responder threshold) for antibodies induced by active immunotherapy; or 5 half-lives for monoclonal antibodies or other biologicals.
 9. Treatment
 - a) in the 4 weeks prior to randomization with any drug or treatment known for the potential to cause major organ system toxicity i.e. drugs that may require periodic safety monitoring of a specific organ or body fluid.
 - b) in the 4 weeks prior to randomization and/or current treatment with any CNS active drugs with the exceptions.
 10. Current chronic treatment (>3 months) with: Strong CYP3A4 inducers or inhibitors; Drugs with a narrow therapeutic index known to be primarily metabolized by CYP2C or CYP3A isoenzymes and sensitive P-gp substrates.
 11. Violations of concomitant medication restrictions.
 12. Donation or loss of 400 mL or more of blood within 8 weeks prior to screening blood sampling and/or lumbar puncture if applicable.
 13. Contraindication or intolerance to MRI investigations.
- Screening part II: Participants fulfilling any of the following criteria based on results from the screening test procedures will be excluded.
14. A positive drug screen, if, in the investigator's opinion, this is due to drug abuse. Participants with a positive drug screen not believed to be related to drug abuse can be re-screened.
 15. Previous participation in a CNP520 study with >3-month exposure to active treatment.
 16. Significantly abnormal laboratory results at screening, meeting the exclusionary alert values specified in the Laboratory Manual. If, in the opinion of the investigator, an abnormal finding is the result of a temporary condition, the laboratory test can be repeated.
 17. Current significant ECG findings from central reader that are assessed as clinically significant by the investigator. QTc interval >500 ms is exclusionary.
 18. Brain MRI results from the central reading showing findings unrelated to AD that, in the opinion of the investigator might be a leading cause of future cognitive decline, might pose a risk to the participant, or might confound MRI assessment for safety monitoring (e.g. extensive white matter lesions, stroke, cerebrovascular disease as evidenced by multiple lacunar infarcts ≤ 20 mm or single infarct >20 mm, evidence of cerebral contusion etc.).
 19. If PET scans are scheduled for this participant: Total dosimetry above the acceptable exposure in the country when combining the previous or planned Nuclear Medicine Radiology exposure and the scheduled study PET scan(s).
 20. If CSF sampling is scheduled for this participant: Contraindication to lumbar puncture e.g. low platelet count, abnormal prothrombin time

international normalized ratio, history of back surgery (except microdiscectomy or laminectomy over one level), signs or symptoms of intracranial pressure etc.

Other protocol defined exclusion criteria may apply.

E.5 END POINT(S):	
E.5.1	Primary End Point (repeat as necessary)²⁶ English - Time to the first event with event defined as the first confirmed diagnosis of MCI due to AD or dementia due to AD. - Change from baseline to month 60 in APCC score.
E.5.1.1	Timepoint(s) of evaluation of this end point English - Baseline to month 60. - Baseline to month 60.
E.5.2	Secondary End Point (repeat as necessary) English - Change from baseline to month 60 in Clinical Dementia Rating Scale - Sum of Boxes (CDRSOB) score. - Frequencies, changes from baseline, Kaplan-Meier estimates when applicable of: Adverse events; Skin events based on a centralized dermatological monitoring; Safety findings from brain structural MRI central reader; Laboratory tests; Vital signs; ECG findings; Prospective suicidality assessment (ideation and behavior) from eC-SSRS. - Change from baseline to month 60 in total RBANS score and individual neurocognitive domain index scores. - Change from baseline to month 60 in total score of the Everyday Cognitive (ECog) scale: ECogsubject and ECog-informant. - Number, intensity and location of microhemorrhages and white matter hyperintensities using the Wahlund scale, both as assessed by central MRI reader. - Change from baseline to month 60 on volume of brain regions as measured by volumetric MRI. - Change from baseline to 24 and 60 months on: amyloid deposition as measured by standardized uptake ratio (SUVR) of radiotracer positron emission tomography (PET) scan; CSF levels of Aβ40, Aβ42; neurodegeneration as measured by CSF levels of total tau and phosphorylated tau. Collected only in participants who consented to additional voluntary procedures.
E.5.2.1	Timepoint(s) of evaluation of this end point English - Baseline to month 60. - Baseline to month 60. - Baseline to month 60. - Baseline to month 60. - Baseline to month 60. - Baseline to month 60. - Baseline to month 24 and 60.

E.6 SCOPE OF THE TRIAL – Tick all boxes where applicable		
E.6.1	Diagnosis	No •
E.6.2	Prophylaxis	No •
E.6.3	Therapy	No •
E.6.4	Safety	Yes •
E.6.5	Efficacy	Yes •
E.6.6	Pharmacokinetic	Yes •
E.6.7	Pharmacodynamic	Yes •
E.6.8	Bioequivalence	No •
E.6.9	Dose Response	Yes •

E.6.10	Pharmacogenetic	Yes •
E.6.11	Pharmacogenomic	Yes •
E.6.12	Pharmacoeconomic	No •
E.6.13	Others	No •
E.6.13.1	If others, specify:	

E.7 TRIAL TYPE AND PHASE ²⁷		
E.7.1	Human pharmacology (Phase I)	No •
Is it:		
E.7.1.1	First administration to humans	No •
E.7.1.2	Bioequivalence study	No •
E.7.1.3	Other:	No •
E.7.1.3.1	If other, please specify:	
E.7.2	Therapeutic exploratory (Phase II)	Yes •
E.7.3	Therapeutic confirmatory (Phase III)	Yes •
E.7.4	Therapeutic use(Phase IV)	No •

E.8 DESIGN OF THE TRIAL		
E.8.1	Controlled	Yes •
If 'Yes', specify:		
E.8.1.1	Randomised:	Yes •
E.8.1.2	Open:	No •
E.8.1.3	Single blind:	No •
E.8.1.4	Double blind:	Yes •
E.8.1.5	Parallel group:	Yes •
E.8.1.6	Cross over:	No •
E.8.1.7	Other:	No •
E.8.1.7.1	If other specify:	
E.8.2	If controlled, specify the comparator:	
E.8.2.1	Other medicinal product(s)	No •
E.8.2.2	Placebo	Yes •
E.8.2.3	Other	No •
E.8.2.3.1	If 'Yes' to other, specify :	
E.8.2.4	Number of treatment arms in the trial	3
E.8.3	Single site in the Member State concerned (see also section G):	No •
E.8.4	Multiple sites in the Member State concerned(see also section G):	Yes •
E.8.4.1	Number of sites anticipated in Member State concerned	2
E.8.5	Multiple Member States:	Yes •
E.8.5.1	Number of sites anticipated in the EEA:	50
E.8.6	Trial involving sites outside the EEA:	
E.8.6.1	Trial being conducted both within and outside the EEA:	Yes •
E.8.6.2	Trial being conducted completely outside of the EEA:	No •
E.8.6.3	If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:	
	Argentina	
	Australia	
	Belgium	
	Canada	
	Chile	
	China	
	Finland	
	France	
	Germany	
	Iceland	
	Israel	
	Italy	
	Japan	
	Korea, Republic of	
	Mexico	
	Netherlands	

	Portugal Singapore South Africa Spain Switzerland Taiwan United Kingdom United States	
E.8.6.4	If E.8.6.1 or E.8.6.2 are Yes, specify the number of sites anticipated outside of the EEA:	129
E.8.7	Trial having an independent data monitoring committee:	Yes •
E.8.8	Definition of the end of trial: If it is the last visit of the last subject, please enter "LVLS". If it is not LVLS provide the definition: English LVLS	
E.8.9	Initial estimate of the duration of the trial ²⁸ (years, months and days)	
E.8.9.1	In the Member State concerned	6 years 11 months days
E.8.9.2	In all countries concerned by the trial	7 years 6 months days
E.8.10	Proposed date of start of recruitment	
E.8.10.1	In the Member State concerned	2017-12-11
E.8.10.2	In any country	2017-08-03

F. POPULATION OF TRIAL SUBJECTS

F.1	AGE RANGE	
F.1.1	Are the trial subjects under 18? If 'Yes', specify the estimated number of subjects planned in each age range for the whole trial: Approx. No. of patients ²⁹	No •
F.1.1.1	In utero	() No •
F.1.1.2	Preterm newborn infants (up to gestational age < 37 weeks)	() No •
F.1.1.3	Newborns (0-27 days)	() No •
F.1.1.4	Infants and toddlers (28 days - 23 months)	() No •
F.1.1.5	Children (2-11 years)	() No •
F.1.1.6	Adolescents (12-17 years)	() No •
F.1.2	Adults (18-64 years)	(400) Yes •
F.1.3	Elderly (>= 65 years)	(1600) Yes •
F.2	GENDER	
F.2.1	Female	Yes •
F.2.2	Male	Yes •
F.3	GROUP OF TRIAL SUBJECTS	
F.3.1	Healthy volunteers	No •
F.3.2	Patients	Yes •
F.3.3	Specific vulnerable populations	Yes •
F.3.3.1	Women of child bearing potential not using contraception	No •
F.3.3.2	Women of child bearing potential using contraception	No •
F.3.3.3	Pregnant women	No •
F.3.3.4	Nursing women	No •
F.3.3.5	Emergency situation	No •
F.3.3.6	Subjects incapable of giving consent personally	No •
F.3.3.6.1	If 'Yes', specify:	
F.3.3.7	Others:	Yes •
F.3.3.7.1	If 'Yes', specify: English	Participants at risk for the onset of clinical symptoms of AD
F.4	PLANNED NUMBER OF SUBJECTS TO BE INCLUDED:	
F.4.1	In the member state	30
F.4.2	For a multinational trial:	
F.4.2.1	In the EEA	708
F.4.2.2	In the whole clinical trial	2000
F.5	PLANS FOR TREATMENT OR CARE AFTER THE SUBJECT HAS ENDED HIS/HER PARTICIPATION IN THE TRIAL. please specify (free text): English Upon study completion (assuming fertility was not met), participants may have the opportunity to enter an extension under a separate study, if eligible.	

**G. CLINICAL TRIAL SITES/INVESTIGATORS IN THE MEMBER STATE
CONCERNED BY THIS REQUEST**

G.1	CO-ORDINATING INVESTIGATOR (for multicentre trial) and principal investigator (for single centre trial)
G.1.1	Given name:
G.1.2	Middle name, if applicable:
G.1.3	Family name:
G.1.4	Qualification (MD.....)
G.1.5	Professional address:
G.1.5	Institution name
G.1.5	Institution department
G.1.5.1	Street address
G.1.5.2	Town/city
G.1.5.3	Post code
G.1.5.4	Country
G.1.6	Telephone number:
G.1.7	Fax number:
G.1.8	E-mail:

G.2	PRINCIPAL INVESTIGATORS	<i>(for multicentre trial ; where necessary, use additional forms)</i>
G.2.1	Given name:	5.1.2.e
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	5.1.2.e
G.2.4	Qualification (MD.....)	5.1.2.e
G.2.5	Professional address:	
G.2.5	Institution name	Brain Research Center Amsterdam
G.2.5	Institution department	
G.2.5.1	Street address	Cronenburg 2
G.2.5.2	Town/city	Amsterdam
G.2.5.3	Post code	1081GN
G.2.5.4	Country	Netherlands
G.2.6	Telephone number:	na
G.2.7	Fax number:	na
G.2.8	E-mail:	

G.2	PRINCIPAL INVESTIGATORS	<i>(for multicentre trial ; where necessary, use additional forms)</i>
G.2.1	Given name:	5.1.2.e
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	5.1.2.e
G.2.4	Qualification (MD.....)	5.1.2.e
G.2.5	Professional address:	
G.2.5	Institution name	Brain Research Center Den Bosch
G.2.5	Institution department	
G.2.5.1	Street address	Statenlaan 37
G.2.5.2	Town/city	's Hertogenbosch
G.2.5.3	Post code	5223 LA
G.2.5.4	Country	Netherlands
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	

G.3 CENTRAL TECHNICAL FACILITIES TO BE USED IN THE CONDUCT OF THE TRIAL	
Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised (repeat as needed for multiple organisations).	
G.3.1	Name of organisation: 5.1.1.c
G.3.2	Department 5.1.2.e
G.3.3	Name of contact person:
G.3.3.1	Given name 5.1.2.e
G.3.3.2	Middle name
G.3.3.3	Family name 5.1.2.e
G.3.4	Address:
G.3.4.1	Street address 5.1.1.c
G.3.4.2	Town/city 5.1.1.c
G.3.4.3	Post code 5.1.1.c
G.3.4.4	Country 5.1.1.c
G.3.5	Telephone number: 5.1.2.e
G.3.6	Fax number: 5.1.2.e
G.3.7	E-mail: 5.1.2.e
G.3.8	Enter the details of any duties subcontracted to this central technical facility in this trial
G.3.8.1	Routine clinical pathology testing No •
G.3.8.2	Clinical chemistry Yes •
G.3.8.3	Clinical haematology Yes •
G.3.8.4	Clinical microbiology No •
G.3.8.5	Histopathology No •
G.3.8.6	Serology/ endocrinology Yes •
G.3.8.7	Analytical chemistry No •
G.3.8.8	ECG analysis/ review No •
G.3.8.9	Medical image analysis/ review - X-ray, MRI, ultrasound, etc. No •
G.3.8.10	Primary/ surrogate endpoint test No •
G.3.8.11	Other Duties subcontracted Yes •
G.3.8.11.1	If 'Yes', specify the other duties Receipt of batch samples from centres/shipment to reference labs; sample analysis; lab supplies

G.3 CENTRAL TECHNICAL FACILITIES TO BE USED IN THE CONDUCT OF THE TRIAL	
Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised (repeat as needed for multiple organisations).	
G.3.1	Name of organisation: 5.1.1.c
G.3.2	Department
G.3.3	Name of contact person:
G.3.3.1	Given name 5.1.2.e
G.3.3.2	Middle name
G.3.3.3	Family name 5.1.2.e
G.3.4	Address:
G.3.4.1	Street address 5.1.1.c
G.3.4.2	Town/city 5.1.1.c
G.3.4.3	Post code 5.1.1.c
G.3.4.4	Country 5.1.1.c
G.3.5	Telephone number: 5.1.2.e
G.3.6	Fax number: 5.1.2.e
G.3.7	E-mail:
G.3.8	Enter the details of any duties subcontracted to this central technical facility in this trial
G.3.8.1	Routine clinical pathology testing No •
G.3.8.2	Clinical chemistry Yes •
G.3.8.3	Clinical haematology No •
G.3.8.4	Clinical microbiology No •
G.3.8.5	Histopathology No •

G.3.8.6	Serology/ endocrinology	No •
G.3.8.7	Analytical chemistry	Yes •
G.3.8.8	ECG analysis/ review	No •
G.3.8.9	Medical image analysis/ review - X-ray, MRI, ultrasound, etc.	No •
G.3.8.10	Primary/ surrogate endpoint test	No •
G.3.8.11	Other Duties subcontracted	Yes •
G.3.8.11.1	If 'Yes', specify the other duties	Assay validation/transfer; sample analysis

G.3		CENTRAL TECHNICAL FACILITIES TO BE USED IN THE CONDUCT OF THE TRIAL	
		Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised (repeat as needed for multiple organisations).	
G.3.1	Name of organisation:	5.1.1.c	
G.3.2	Department	5.1.1.c	
G.3.3	Name of contact person:		
G.3.3.1	Given name	5.1.2.e	
G.3.3.2	Middle name		
G.3.3.3	Family name	5.1.2.e	
G.3.4	Address:		
G.3.4.1	Street address	5.1.1.c	
G.3.4.2	Town/city	5.1.1.c	
G.3.4.3	Post code	5.1.1.c	
G.3.4.4	Country	5.1.1.c	
G.3.5	Telephone number:	5.1.2.e	
G.3.6	Fax number:		
G.3.7	E-mail:	5.1.2.e	
G.3.8	Enter the details of any duties subcontracted to this central technical facility in this trial		
G.3.8.1	Routine clinical pathology testing	No •	
G.3.8.2	Clinical chemistry	No •	
G.3.8.3	Clinical haematology	No •	
G.3.8.4	Clinical microbiology	No •	
G.3.8.5	Histopathology	No •	
G.3.8.6	Serology/ endocrinology	No •	
G.3.8.7	Analytical chemistry	No •	
G.3.8.8	ECG analysis/ review	Yes •	
G.3.8.9	Medical image analysis/ review - X-ray, MRI, ultrasound, etc.	No •	
G.3.8.10	Primary/ surrogate endpoint test	No •	
G.3.8.11	Other Duties subcontracted	Yes •	
G.3.8.11.1	If 'Yes', specify the other duties	Central reading re: ECG; eCSSRS	

G.3		CENTRAL TECHNICAL FACILITIES TO BE USED IN THE CONDUCT OF THE TRIAL	
		Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised (repeat as needed for multiple organisations).	
G.3.1	Name of organisation:	5.1.1.c	
G.3.2	Department	5.1.1.c	
G.3.3	Name of contact person:		
G.3.3.1	Given name	5.1.2.e	
G.3.3.2	Middle name		
G.3.3.3	Family name	5.1.2.e	
G.3.4	Address:		
G.3.4.1	Street address	5.1.1.c	
G.3.4.2	Town/city	5.1.1.c	
G.3.4.3	Post code	5.1.1.c	
G.3.4.4	Country	5.1.1.c	
G.3.5	Telephone number:	5.1.2.e	
G.3.6	Fax number:		

G.3.7	E-mail:	5.1.2.e
G.3.8	Enter the details of any duties subcontracted to this central technical facility in this trial	
G.3.8.1	Routine clinical pathology testing	No •
G.3.8.2	Clinical chemistry	No •
G.3.8.3	Clinical haematology	No •
G.3.8.4	Clinical microbiology	No •
G.3.8.5	Histopathology	No •
G.3.8.6	Serology/ endocrinology	No •
G.3.8.7	Analytical chemistry	No •
G.3.8.8	ECG analysis/ review	No •
G.3.8.9	Medical image analysis/ review - X-ray, MRI, ultrasound, etc.	Yes •
G.3.8.10	Primary/ surrogate endpoint test	No •
G.3.8.11	Other Duties subcontracted	Yes •
G.3.8.11.1	If 'Yes', specify the other duties	Site training; CRF/data review; central reading/image analysis/archiving of MRI and Tau PET scans

G.3 CENTRAL TECHNICAL FACILITIES TO BE USED IN THE CONDUCT OF THE TRIAL		
Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised (repeat as needed for multiple organisations).		
G.3.1	Name of organisation:	5.1.1.c
G.3.2	Department	
G.3.3	Name of contact person:	
G.3.3.1	Given name	5.1.2.e
G.3.3.2	Middle name	
G.3.3.3	Family name	5.1.2.e
G.3.4	Address:	
G.3.4.1	Street address	5.1.1.c
G.3.4.2	Town/city	5.1.1.c
G.3.4.3	Post code	5.1.1.c
G.3.4.4	Country	5.1.1.c
G.3.5	Telephone number:	5.1.2.e
G.3.6	Fax number:	
G.3.7	E-mail:	5.1.2.e
G.3.8	Enter the details of any duties subcontracted to this central technical facility in this trial	
G.3.8.1	Routine clinical pathology testing	No •
G.3.8.2	Clinical chemistry	No •
G.3.8.3	Clinical haematology	No •
G.3.8.4	Clinical microbiology	No •
G.3.8.5	Histopathology	No •
G.3.8.6	Serology/ endocrinology	No •
G.3.8.7	Analytical chemistry	No •
G.3.8.8	ECG analysis/ review	No •
G.3.8.9	Medical image analysis/ review - X-ray, MRI, ultrasound, etc.	Yes •
G.3.8.10	Primary/ surrogate endpoint test	No •
G.3.8.11	Other Duties subcontracted	Yes •
G.3.8.11.1	If 'Yes', specify the other duties	Central dermatology, photography, monitoring & review; training

G.3 CENTRAL TECHNICAL FACILITIES TO BE USED IN THE CONDUCT OF THE TRIAL		
Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised (repeat as needed for multiple organisations).		
G.3.1	Name of organisation:	5.1.1.c
G.3.2	Department	5.1.2.e
G.3.3	Name of contact person:	

G.3.3.1	Given name	5.1.2.e
G.3.3.2	Middle name	
G.3.3.3	Family name	5.1.2.e
G.3.4	Address:	
G.3.4.1	Street address	5.1.1.c
G.3.4.2	Town/city	5.1.1.c
G.3.4.3	Post code	5.1.1.c
G.3.4.4	Country	5.1.1.c
G.3.5	Telephone number:	5.1.2.e
G.3.6	Fax number:	
G.3.7	E-mail:	5.1.2.e
G.3.8	Enter the details of any duties subcontracted to this central technical facility in this trial	
G.3.8.1	Routine clinical pathology testing	No •
G.3.8.2	Clinical chemistry	No •
G.3.8.3	Clinical haematology	No •
G.3.8.4	Clinical microbiology	No •
G.3.8.5	Histopathology	No •
G.3.8.6	Serology/ endocrinology	No •
G.3.8.7	Analytical chemistry	No •
G.3.8.8	ECG analysis/ review	No •
G.3.8.9	Medical image analysis/ review - X-ray, MRI, ultrasound, etc.	No •
G.3.8.10	Primary/ surrogate endpoint test	No •
G.3.8.11	Other Duties subcontracted	Yes •
G.3.8.11.1	If 'Yes', specify the other duties	Supply of Amyloid PET ligand (flutemetamol) to various sites in various countries

G.3 CENTRAL TECHNICAL FACILITIES TO BE USED IN THE CONDUCT OF THE TRIAL		
Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised (repeat as needed for multiple organisations).		
G.3.1	Name of organisation:	5.1.1.c
G.3.2	Department	5.1.1.c
G.3.3	Name of contact person:	
G.3.3.1	Given name	5.1.2.e
G.3.3.2	Middle name	
G.3.3.3	Family name	5.1.2.e
G.3.4	Address:	
G.3.4.1	Street address	5.1.1.c
G.3.4.2	Town/city	5.1.1.c
G.3.4.3	Post code	5.1.1.c
G.3.4.4	Country	5.1.1.c
G.3.5	Telephone number:	5.1.2.e
G.3.6	Fax number:	
G.3.7	E-mail:	5.1.2.e
G.3.8	Enter the details of any duties subcontracted to this central technical facility in this trial	
G.3.8.1	Routine clinical pathology testing	No •
G.3.8.2	Clinical chemistry	No •
G.3.8.3	Clinical haematology	No •
G.3.8.4	Clinical microbiology	No •
G.3.8.5	Histopathology	No •
G.3.8.6	Serology/ endocrinology	No •
G.3.8.7	Analytical chemistry	No •
G.3.8.8	ECG analysis/ review	No •
G.3.8.9	Medical image analysis/ review - X-ray, MRI, ultrasound, etc.	Yes •
G.3.8.10	Primary/ surrogate endpoint test	No •
G.3.8.11	Other Duties subcontracted	Yes •
G.3.8.11.1	If 'Yes', specify the other duties	Amyloid/Tau biomarker supply/expertise; PET reading/analysis/archiving; CRF/data review;

G.3 CENTRAL TECHNICAL FACILITIES TO BE USED IN THE CONDUCT OF THE TRIAL	
Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised (repeat as needed for multiple organisations).	
G.3.1	Name of organisation: 5.1.1.c
G.3.2	Department 5.1.1.c
G.3.3	Name of contact person:
G.3.3.1	Given name 5.1.2.e
G.3.3.2	Middle name
G.3.3.3	Family name 5.1.2.e
G.3.4	Address:
G.3.4.1	Street address 5.1.1.c
G.3.4.2	Town/city 5.1.1.c
G.3.4.3	Post code 5.1.1.c
G.3.4.4	Country 5.1.1.c
G.3.5	Telephone number: 5.1.2.e
G.3.6	Fax number:
G.3.7	E-mail: 5.1.2.e
G.3.8	Enter the details of any duties subcontracted to this central technical facility in this trial
G.3.8.1	Routine clinical pathology testing No •
G.3.8.2	Clinical chemistry No •
G.3.8.3	Clinical haematology No •
G.3.8.4	Clinical microbiology No •
G.3.8.5	Histopathology No •
G.3.8.6	Serology/ endocrinology No •
G.3.8.7	Analytical chemistry No •
G.3.8.8	ECG analysis/ review No •
G.3.8.9	Medical image analysis/ review - X-ray, MRI, ultrasound, etc. No •
G.3.8.10	Primary/ surrogate endpoint test No •
G.3.8.11	Other Duties subcontracted Yes •
G.3.8.11.1	If 'Yes', specify the other duties Training; reading/archiving re:scales/MCI&AD diagnosis; adjudication;eSource data collection

G.4 NETWORKS TO BE INVOLVED IN THE TRIAL (e.g. Paediatric Networks involved in the trial)	
G.4.1	Name of organisation:
G.4.2	Name of contact person:
G.4.2.1	Given name
G.4.2.2	Middle name
G.4.2.3	Family name
G.4.3	Address:
G.4.3.1	Street address
G.4.3.2	Town/city
G.4.3.3	Post code
G.4.3.4	Country
G.4.4	Telephone number:
G.4.5	Fax number:
G.4.6	E-mail:
G.4.7	Activities carried out by the network:

G.5 ORGANISATIONS TO WHOM THE SPONSOR HAS TRANSFERRED TRIAL RELATED DUTIES AND FUNCTIONS	
G.5.1	Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third Yes •

party?		
Repeat as necessary for multiple organisations:		
G.5.1.1	Organisation name:	Parexel International GmbH
G.5.1.2	Organisation department	CTRS-PL
G.5.1.3	Name of contact person :	
G.5.1.3.1	Given name	5.1.2.e
G.5.1.3.2	Middle name	
G.5.1.3.3	Family name	5.1.2.e
G.5.1.4	Address:	
G.5.1.4.1	Street address	Klinikum Westend, Haus 18, Spandauer Damm 130
G.5.1.4.2	Town/city	Berlin
G.5.1.4.3	Post code	D-14050
G.5.1.4.4	Country	Germany
G.5.1.5	Telephone number:	+49 30 5.1.2.e
G.5.1.6	Fax number:	+49-30 5.1.2.e
G.5.1.7	E-mail:	5.1.2.e@parexel.com
G.5.1.8	All tasks of the sponsor	No •
G.5.1.9	Monitoring	No •
G.5.1.10	Regulatory (e.g. preparation of applications to CA and ethics committee)	Yes •
G.5.1.11	Investigator recruitment	No •
G.5.1.12	IVRS ³⁰ – treatment randomisation	No •
G.5.1.13	Data management	No •
G.5.1.14	E-data capture	No •
G.5.1.15	SUSAR reporting	No •
G.5.1.16	Quality assurance auditing	No •
G.5.1.17	Statistical analysis	No •
G.5.1.18	Medical writing	No •
G.5.1.19	Other duties subcontracted	No •
G.5.1.19.1	If 'Yes' to other, please specify:	
G.5	ORGANISATIONS TO WHOM THE SPONSOR HAS TRANSFERRED TRIAL RELATED DUTIES AND FUNCTIONS	
G.5.1	Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third party?	Yes •
Repeat as necessary for multiple organisations:		
G.5.1.1	Organisation name:	5.1.1.c
G.5.1.2	Organisation department	5.1.1.c
G.5.1.3	Name of contact person :	
G.5.1.3.1	Given name	5.1.2.e
G.5.1.3.2	Middle name	
G.5.1.3.3	Family name	5.1.2.e
G.5.1.4	Address:	
G.5.1.4.1	Street address	5.1.1.c
G.5.1.4.2	Town/city	5.1.1.c
G.5.1.4.3	Post code	5.1.1.c
G.5.1.4.4	Country	5.1.1.c
G.5.1.5	Telephone number:	5.1.2.e
G.5.1.6	Fax number:	
G.5.1.7	E-mail:	5.1.2.e
G.5.1.8	All tasks of the sponsor	No •
G.5.1.9	Monitoring	No •
G.5.1.10	Regulatory (e.g. preparation of applications to CA and ethics committee)	No •
G.5.1.11	Investigator recruitment	No •
G.5.1.12	IVRS ³⁰ – treatment randomisation	No •
G.5.1.13	Data management	No •
G.5.1.14	E-data capture	No •
G.5.1.15	SUSAR reporting	No •

G.5.1.16	Quality assurance auditing	No ●
G.5.1.17	Statistical analysis	No ●
G.5.1.18	Medical writing	No ●
G.5.1.19	Other duties subcontracted	Yes ●
G.5.1.19.1	If 'Yes' to other, please specify: Regional warehousing/auxiliary labelling	
G.5	ORGANISATIONS TO WHOM THE SPONSOR HAS TRANSFERRED TRIAL RELATED DUTIES AND FUNCTIONS	
G.5.1	Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third party?	Yes ●
Repeat as necessary for multiple organisations:		
G.5.1.1	Organisation name:	5.1.1.c [REDACTED]
G.5.1.2	Organisation department	5.1.1.c [REDACTED]
G.5.1.3	Name of contact person :	
G.5.1.3.1	Given name	5.1.2.e [REDACTED]
G.5.1.3.2	Middle name	
G.5.1.3.3	Family name	5.1.2.e [REDACTED]
G.5.1.4	Address:	
G.5.1.4.1	Street address	5.1.1.c [REDACTED]
G.5.1.4.2	Town/city	5.1.1.c [REDACTED]
G.5.1.4.3	Post code	5.1.1.c [REDACTED]
G.5.1.4.4	Country	5.1.1.c [REDACTED]
G.5.1.5	Telephone number:	5.1.2.e [REDACTED]
G.5.1.6	Fax number:	
G.5.1.7	E-mail:	5.1.2.e [REDACTED]
G.5.1.8	All tasks of the sponsor	No ●
G.5.1.9	Monitoring	No ●
G.5.1.10	Regulatory (e.g. preparation of applications to CA and ethics committee)	No ●
G.5.1.11	Investigator recruitment	No ●
G.5.1.12	IVRS ³⁰ – treatment randomisation	No ●
G.5.1.13	Data management	No ●
G.5.1.14	E-data capture	No ●
G.5.1.15	SUSAR reporting	No ●
G.5.1.16	Quality assurance auditing	No ●
G.5.1.17	Statistical analysis	No ●
G.5.1.18	Medical writing	No ●
G.5.1.19	Other duties subcontracted	Yes ●
G.5.1.19.1	If 'Yes' to other, please specify: Regional warehousing/auxiliary labelling	
G.5	ORGANISATIONS TO WHOM THE SPONSOR HAS TRANSFERRED TRIAL RELATED DUTIES AND FUNCTIONS	
G.5.1	Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third party?	Yes ●
Repeat as necessary for multiple organisations:		
G.5.1.1	Organisation name:	5.1.1.c [REDACTED]
G.5.1.2	Organisation department	5.1.1.c [REDACTED]
G.5.1.3	Name of contact person :	
G.5.1.3.1	Given name	5.1.2.e [REDACTED]
G.5.1.3.2	Middle name	
G.5.1.3.3	Family name	5.1.2.e [REDACTED]
G.5.1.4	Address:	
G.5.1.4.1	Street address	5.1.1.c [REDACTED]
G.5.1.4.2	Town/city	5.1.1.c [REDACTED]
G.5.1.4.3	Post code	5.1.1.c [REDACTED]
G.5.1.4.4	Country	5.1.1.c [REDACTED]
G.5.1.5	Telephone number:	5.1.2.e [REDACTED]
G.5.1.6	Fax number:	
G.5.1.7	E-mail:	5.1.2.e [REDACTED]

G.5.1.8	All tasks of the sponsor	No •
G.5.1.9	Monitoring	No •
G.5.1.10	Regulatory (e.g. preparation of applications to CA and ethics committee)	No •
G.5.1.11	Investigator recruitment	No •
G.5.1.12	IVRS ³⁰ – treatment randomisation	No •
G.5.1.13	Data management	No •
G.5.1.14	E-data capture	No •
G.5.1.15	SUSAR reporting	No •
G.5.1.16	Quality assurance auditing	No •
G.5.1.17	Statistical analysis	No •
G.5.1.18	Medical writing	No •
G.5.1.19	Other duties subcontracted	Yes •
G.5.1.19.1	If 'Yes' to other, please specify: Regional warehousing/auxiliary labelling	
G.5	ORGANISATIONS TO WHOM THE SPONSOR HAS TRANSFERRED TRIAL RELATED DUTIES AND FUNCTIONS	
G.5.1	Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third party?	Yes •
Repeat as necessary for multiple organisations:		
G.5.1.1	Organisation name:	5.1.1.c
G.5.1.2	Organisation department	5.1.1.c
G.5.1.3	Name of contact person :	
G.5.1.3.1	Given name	5.1.2.e
G.5.1.3.2	Middle name	
G.5.1.3.3	Family name	5.1.2.e
G.5.1.4	Address:	
G.5.1.4.1	Street address	5.1.1.c
G.5.1.4.2	Town/city	5.1.1.c
G.5.1.4.3	Post code	5.1.1.c
G.5.1.4.4	Country	5.1.1.c
G.5.1.5	Telephone number:	5.1.2.e
G.5.1.6	Fax number:	
G.5.1.7	E-mail:	5.1.2.e
G.5.1.8	All tasks of the sponsor	No •
G.5.1.9	Monitoring	No •
G.5.1.10	Regulatory (e.g. preparation of applications to CA and ethics committee)	No •
G.5.1.11	Investigator recruitment	No •
G.5.1.12	IVRS ³⁰ – treatment randomisation	Yes •
G.5.1.13	Data management	No •
G.5.1.14	E-data capture	No •
G.5.1.15	SUSAR reporting	No •
G.5.1.16	Quality assurance auditing	No •
G.5.1.17	Statistical analysis	No •
G.5.1.18	Medical writing	No •
G.5.1.19	Other duties subcontracted	Yes •
G.5.1.19.1	If 'Yes' to other, please specify: Subject randomization management; Drug supply management; IRT services	
G.5	ORGANISATIONS TO WHOM THE SPONSOR HAS TRANSFERRED TRIAL RELATED DUTIES AND FUNCTIONS	
G.5.1	Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third party?	Yes •
Repeat as necessary for multiple organisations:		
G.5.1.1	Organisation name:	5.1.1.c
G.5.1.2	Organisation department	
G.5.1.3	Name of contact person :	
G.5.1.3.1	Given name	5.1.2.e

G.5.1.3.2	Middle name		
G.5.1.3.3	Family name		
G.5.1.4	Address:		
G.5.1.4.1	Street address	5.1.1.c	
G.5.1.4.2	Town/city	5.1.1.c	
G.5.1.4.3	Post code	5.1.1.c	
G.5.1.4.4	Country	5.1.1.c	
G.5.1.5	Telephone number:		
G.5.1.6	Fax number:		
G.5.1.7	E-mail:		
G.5.1.8	All tasks of the sponsor		No •
G.5.1.9	Monitoring		No •
G.5.1.10	Regulatory (e.g. preparation of applications to CA and ethics committee)		No •
G.5.1.11	Investigator recruitment		No •
G.5.1.12	IVRS ³⁰ – treatment randomisation		No •
G.5.1.13	Data management		No •
G.5.1.14	E-data capture		No •
G.5.1.15	SUSAR reporting		No •
G.5.1.16	Quality assurance auditing		No •
G.5.1.17	Statistical analysis		No •
G.5.1.18	Medical writing		No •
G.5.1.19	Other duties subcontracted		Yes •
G.5.1.19.1	If 'Yes' to other, please specify:	Long term Sample storage and shipments	
G.5	ORGANISATIONS TO WHOM THE SPONSOR HAS TRANSFERRED TRIAL RELATED DUTIES AND FUNCTIONS		
G.5.1	Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third party?		Yes •
Repeat as necessary for multiple organisations:			
G.5.1.1	Organisation name:	5.1.1.c	
G.5.1.2	Organisation department	5.1.2.e	
G.5.1.3	Name of contact person :		
G.5.1.3.1	Given name	5.1.2.e	
G.5.1.3.2	Middle name		
G.5.1.3.3	Family name	5.1.2.e	
G.5.1.4	Address:		
G.5.1.4.1	Street address	5.1.1.c	
G.5.1.4.2	Town/city	5.1.1.c	
G.5.1.4.3	Post code	5.1.1.c	
G.5.1.4.4	Country	5.1.1.c	
G.5.1.5	Telephone number:	5.1.2.e	
G.5.1.6	Fax number:	5.1.2.e	
G.5.1.7	E-mail:	5.1.2.e	
G.5.1.8	All tasks of the sponsor		No •
G.5.1.9	Monitoring		No •
G.5.1.10	Regulatory (e.g. preparation of applications to CA and ethics committee)		No •
G.5.1.11	Investigator recruitment		No •
G.5.1.12	IVRS ³⁰ – treatment randomisation		No •
G.5.1.13	Data management		No •
G.5.1.14	E-data capture		No •
G.5.1.15	SUSAR reporting		No •
G.5.1.16	Quality assurance auditing		No •
G.5.1.17	Statistical analysis		No •
G.5.1.18	Medical writing		No •
G.5.1.19	Other duties subcontracted		Yes •
G.5.1.19.1	If 'Yes' to other, please specify:	Protocol, analysis plan & IDMC review; SAE programming & SAE narratives; IDMC reports & liaison	

G.5	ORGANISATIONS TO WHOM THE SPONSOR HAS TRANSFERRED TRIAL RELATED DUTIES AND FUNCTIONS	
G.5.1	Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third party?	Yes •
Repeat as necessary for multiple organisations:		
G.5.1.1	Organisation name:	5.1.1.c
G.5.1.2	Organisation department	
G.5.1.3	Name of contact person :	
G.5.1.3.1	Given name	5.1.2.e
G.5.1.3.2	Middle name	
G.5.1.3.3	Family name	5.1.2.e
G.5.1.4	Address:	
G.5.1.4.1	Street address	5.1.1.c
G.5.1.4.2	Town/city	5.1.1.c
G.5.1.4.3	Post code	5.1.1.c
G.5.1.4.4	Country	5.1.1.c
G.5.1.5	Telephone number:	5.1.2.e
G.5.1.6	Fax number:	
G.5.1.7	E-mail:	5.1.2.e
G.5.1.8	All tasks of the sponsor	No •
G.5.1.9	Monitoring	No •
G.5.1.10	Regulatory (e.g. preparation of applications to CA and ethics committee)	No •
G.5.1.11	Investigator recruitment	No •
G.5.1.12	IVRS ³⁰ – treatment randomisation	No •
G.5.1.13	Data management	No •
G.5.1.14	E-data capture	No •
G.5.1.15	SUSAR reporting	No •
G.5.1.16	Quality assurance auditing	No •
G.5.1.17	Statistical analysis	No •
G.5.1.18	Medical writing	No •
G.5.1.19	Other duties subcontracted	Yes •
G.5.1.19.1	If 'Yes' to other, please specify:	5.1.1.c Data collection and management
G.5	ORGANISATIONS TO WHOM THE SPONSOR HAS TRANSFERRED TRIAL RELATED DUTIES AND FUNCTIONS	
G.5.1	Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third party?	Yes •
Repeat as necessary for multiple organisations:		
G.5.1.1	Organisation name:	5.1.1.c
G.5.1.2	Organisation department	
G.5.1.3	Name of contact person :	
G.5.1.3.1	Given name	5.1.2.e
G.5.1.3.2	Middle name	
G.5.1.3.3	Family name	5.1.2.e
G.5.1.4	Address:	
G.5.1.4.1	Street address	5.1.1.c
G.5.1.4.2	Town/city	5.1.1.c
G.5.1.4.3	Post code	5.1.1.c
G.5.1.4.4	Country	5.1.1.c
G.5.1.5	Telephone number:	5.1.2.e
G.5.1.6	Fax number:	
G.5.1.7	E-mail:	5.1.2.e
G.5.1.8	All tasks of the sponsor	No •
G.5.1.9	Monitoring	No •
G.5.1.10	Regulatory (e.g. preparation of applications to CA and ethics committee)	No •

G.5.1.11	Investigator recruitment	No •
G.5.1.12	IVRS ³⁰ – treatment randomisation	No •
G.5.1.13	Data management	No •
G.5.1.14	E-data capture	No •
G.5.1.15	SUSAR reporting	No •
G.5.1.16	Quality assurance auditing	No •
G.5.1.17	Statistical analysis	No •
G.5.1.18	Medical writing	No •
G.5.1.19	Other duties subcontracted	Yes •
G.5.1.19.1	If 'Yes' to other, please specify:	Implementation and management of study website; Management of site recruitment tools; Travel support
G.5 ORGANISATIONS TO WHOM THE SPONSOR HAS TRANSFERRED TRIAL RELATED DUTIES AND FUNCTIONS		
G.5.1	Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third party?	Yes •
Repeat as necessary for multiple organisations:		
G.5.1.1	Organisation name:	5.1.1.c
G.5.1.2	Organisation department	
G.5.1.3	Name of contact person :	
G.5.1.3.1	Given name	
G.5.1.3.2	Middle name	
G.5.1.3.3	Family name	
G.5.1.4	Address:	
G.5.1.4.1	Street address	5.1.1.c
G.5.1.4.2	Town/city	5.1.1.c
G.5.1.4.3	Post code	5.1.1.c
G.5.1.4.4	Country	5.1.1.c
G.5.1.5	Telephone number:	
G.5.1.6	Fax number:	
G.5.1.7	E-mail:	
G.5.1.8	All tasks of the sponsor	No •
G.5.1.9	Monitoring	No •
G.5.1.10	Regulatory (e.g. preparation of applications to CA and ethics committee)	No •
G.5.1.11	Investigator recruitment	No •
G.5.1.12	IVRS ³⁰ – treatment randomisation	No •
G.5.1.13	Data management	No •
G.5.1.14	E-data capture	No •
G.5.1.15	SUSAR reporting	No •
G.5.1.16	Quality assurance auditing	No •
G.5.1.17	Statistical analysis	No •
G.5.1.18	Medical writing	No •
G.5.1.19	Other duties subcontracted	Yes •
G.5.1.19.1	If 'Yes' to other, please specify:	Rental of -70 freezer to BRC Den Bosch

H. COMPETENT AUTHORITY / ETHICS COMMITTEE IN THE MEMBER STATE CONCERNED BY THIS REQUEST

H.1 TYPE OF APPLICATION		
If this application is addressed to the Competent Authority, please tick the Ethics Committee box and give information on the Ethics committee concerned. If this application is addressed to the Ethics Committee, please tick the Competent Authority box and give the information on the Competent Authority concerned.		
H.1.1	Competent Authority	No ●
H.1.2	Ethics Committee	Yes ●

H.2 INFORMATION ON ETHICS COMMITTEE		
H.2.1	Name:	METc VUmc
H.2.2	Address	
H.2.2.1	Street address	van der Boechorststraat 7
H.2.2.2	Town/city	Amsterdam
H.2.2.3	Post code	1081 BT
H.2.2.4	Country	Netherlands
H.2.3	Date of submission:	2017-09-19

H.3 OPINION		
H.3.1	To be requested	No ●
H.3.2	Pending	No ●
H.3.3	Given	Yes ●
If 'Given', specify:		
H.3.3.1	Date of opinion:	2018-07-06
H.3.3.2	Opinion favourable	No ●
H.3.3.3	Opinion not favourable	No ●
If not favourable, give:		
H.3.3.3.1	The reasons	
H.3.3.3.2	The eventual anticipated date of resubmission:	

I. SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

I.1	I hereby confirm that /confirm on behalf of the sponsor (delete which is not applicable) that: ☐ the information provided is complete; ☐ the attached documents contain an accurate account of the information available; ☐ the clinical trial will be conducted in accordance with the protocol; and ☐ the clinical trial will be conducted, and SUSARs and result-related information will be reported, in accordance with the applicable legislation.
I.2	APPLICANT OF THE REQUEST FOR THE COMPETENT AUTHORITY (as stated in section C.1):
I.2.1	Date:
I.2.2	Signature ³¹ :
I.2.3	Print name:
I.3	APPLICANT OF THE REQUEST FOR THE ETHICS COMMITTEE (as stated in section C.2):
I.3.1	Date:
I.3.2	Signature ³² :
I.3.3	Print name:

ENDNOTES

- ¹ Any translation of the protocol should be assigned the same date and version as those in the original document.
- ² International Standard Randomised Controlled Trial Number. Sponsors may wish to use an International Standardised Random Controlled Trial Number (ISRCTN) to identify their trial in addition to the EudraCT number; for instance if their trial is part of a multinational trial with sites outside the Community. They can obtain the number and guidance from the Current Controlled Trials website <http://www.controlled-trials.com/isrctn> to which there is a link from the EudraCT database website <http://eudract.ema.europa.eu>. When available they should provide it in Section A.6 of the application form.
- ³ US National Clinical Trial (NCT) Numbers required on the FDA clinical trial application form.
- ⁴ For a resubmission following previous withdrawal of an application or unfavourable opinion of an ethics committee, or previous withdrawal of an application or refusal of a request by the competent authority, enter a letter in the sequence, A for first resubmission, B for second, C for third et seq.
- ⁵ In accordance with Article 19 of Directive 2001/20/EC.
- ⁶ The contact point should give functional information rather than details of one "person", in order to avoid the need for update and maintenance of these contact details.
- ⁷ This requires a EudraLink account. (See <https://eudract.ema.europa.eu/document.html> for details)
- ⁸ According to national legislation.
- ⁹ Available from the Summary of Product Characteristics (SmPC)
- ¹⁰ According to the Community register on orphan medicinal products (Regulation (EC) n° 141/2000): <http://ec.europa.eu/enterprise/pharmaceuticals/register/index.htm>
- ¹¹ Committee for Medicinal Products for Human Use of the European Medicines Agency
- ¹² To be provided only when there is No trade name. This is the name routinely used by a sponsor to identify the IMP in the CT documentation (protocol, IB...).
- ¹³ To be provided only when there is No trade name. This is a code designated by the sponsor which represents the name routinely used by the sponsor to identify the product in the CT documentation. For example, a code may be used for combinations of drugs or drugs and devices.
- ¹⁴ Available from the Summary of Product Characteristics (SmPC).
- ¹⁵ Chemical Abstracts Service.
- ¹⁶ Complete also section D.4 Cell therapy as defined in Annex 1 part IV of Directive 2001/83/EC as amended.
- ¹⁷ Complete also section D.5 Gene Therapy as defined in Annex 1 part IV of Directive 2001/83/EC as amended.
- ¹⁸ Complete also section D.6 - Tissue Engineered Product as defined in Article 2(1)(b) of Regulation 1394/2007/EC.
- ¹⁹ Complete also section D.7
- ²⁰ The mode of action should briefly describe the chemical, biochemical, immunological or biological means the IMP uses to effect its pharmaceutical action.
- ²¹ Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/2007 19 July 2007
- ²² In accordance with paragraph 38 of Annex 13 of Volume 4 of the Rules Governing Medical Products in the European Union.
- ²³ In the case of healthy volunteer trials, the intended indication for the product under development should be provided.
- ²⁴ Applicants are encouraged to provide the MedDRA lower level term if applicable and classification code. These can be accessed from the EMEA EudraCT website (<http://eudract.ema.europa.eu/>).
- ²⁵ Points to consider on the calculation and reporting of the prevalence of a condition for Orphan drug designation: COM/436/01 (<http://www.ema.europa.eu/htms/human/orphans/intro.htm>).
- ²⁶ The protocol will usually identify a single primary end point but there may be a co-primary end point in some cases and/or a number of secondary end points.
- ²⁷ The descriptions of the trial types provided are those recommended in preference to Phases. See page 5 of Community guideline CPMP/ICH/291/95. The development of a new indication after initial approval of a medicine should be considered as a new development plan.
- ²⁸ From the first inclusion until the last visit of the last subject.
- ²⁹ These numbers will be initial estimates. Applicants will not be required to update this information nor do they constitute an authorisation or restriction on the inclusion of these numbers of patients in the trial. The numbers of subjects whose inclusion is authorised are those set out in the authorised version of the protocol, or subsequent authorised amendments.
- ³⁰ Interactive Voice Response System: commonly used for randomisation of treatment and controlling the shipment of stock of product.
- ³¹ On an application to the Competent Authority only, the applicant to the Competent Authority needs to sign.

³² On an application to the Ethics Committee only, the applicant to the Ethics Committee needs to sign.

2016-002976-28

33

A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)

To evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)

CCNP520A2202J

v02

2018-12-18

NCT03131453

0

100000075938

2

0

999999000410

1

Novartis Pharma AG

Lichtstrasse 35

Basel

CH-4056

100000000536

12

5.1.2.e @novartis.com

+41 5.1.2.e

5.1.2.e

5.1.2.e

Novartis Pharma Arzneimittel GmbH

Roonstrasse 25

Nürnberg

D-90429

100000000403

5.1.2.e [REDACTED]@novartis.com

+49

5.1.2.e [REDACTED]

5.1.2.e [REDACTED]

5.1.2.e [REDACTED]

+49

5.1.2.e [REDACTED]

5.1.2.e [REDACTED]

5.1.2.e [REDACTED]

5.1.2.e [REDACTED]

5.1.2.e [REDACTED]

Novartis Pharma AG

Lichtstrasse 35

Basel

CH-4056

100000000536

12

5.1.2.e [REDACTED]@novartis.com

+44 5.1.2.e [REDACTED]

+44 5.1.2.e [REDACTED]

Clinical Trial Information Desk

Novartis Pharma AG

100000000536

12

999999000400

1

Parexel International Romania s.r.l.

89-97 Grigore Alexandrescu St.

Bucharest

010624

100000000505

13

5.1.2.e @novartis.com

+40

31

5.1.2.e

5.1.2.e

+40

37

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0

0

999999000403

1

Novartis Pharma B.V.

Raapopseweg 1

Arnhem

6824 DP

100000000478

11

5.1.2.e @novartis.com

+31 26 5.1.2.e

na

5.1.2.e

5.1.2.e

100000075981

4

0

-1

0

-1

-1

-1

-1

1

0

0

1

100000000337

11

100000000394

11

100000000395

11

100000000403

12

100000000422

11

100000000430

11

100000000478

11

100000000501

11

100000000529

12

100000000556

11

0

1

1

0

CNP520 15 mg

CNP520

100000073375

12

0

96 months

-1

999999000000

1

999999000000

1

1

15

999999000170

1

100000073619

5

100000073619

5

1

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

CNP520 is an orally active beta-secretase (BACE-1) inhibitor

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Not established

CNP520

SUB166276

999999000170

1

999999000116

1

15

100000075981

4

0

-1

0

-1

-1

-1

-1

1

0

0

1

100000000337

11

100000000394

11

100000000395

11

100000000403

12

100000000422

11

100000000430

11

100000000478

11

100000000501

11

100000000529

12

100000000556

11

0

1

1

0

CNP520 50 mg

CNP520

100000073375

12

0

96 months

-1

999999000000

1

999999000000

1

1

50

999999000170

1

100000073619

5

100000073619

5

1

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

CNP520 is an orally active beta-secretase (BACE-1) inhibitor

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Not established

CNP520

SUB166276

999999000170

1

999999000116

1

50

100000073619

5

100000073375

12

PR1

0

Pregelatinized starch, microcrystalline cellulose, magnesium stearate. □
Capsule - gelatin, titanium oxide, iron oxide, red/Ferric oxide.

PR2

0

Pregelatinized starch, microcrystalline cellulose, magnesium stearate. □

Capsule - gelatin, titanium oxide, iron oxide, red/Ferric oxide.

1

PR1

PR2

PL1

Novartis Pharma Arzneimittel GmbH

Roonstrasse 25

Nürnberg

D-90429

100000000403

12

999999000394

1

DE_BY_05_MIA_2016_0088/55.2-2678.3-3-297

Alzheimer's disease

Dementia

999999000431

1

0

20.0

LLT

10001896

Alzheimer's disease

100000004852

- To demonstrate the effect of CNP520 vs placebo on time to diagnosis of MCI due to AD or dementia due to AD, whichever occurs first during the course of the study. □
- To demonstrate the effect of CNP520 vs placebo on cognition using APCC.

Key secondary objective: □

- To demonstrate the effects of CNP520 vs placebo on global clinical status. □

Secondary objectives: □

- To demonstrate the safety and tolerability of CNP520 vs placebo. □

- To demonstrate the effects of CNP520 vs placebo on cognition using Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). □

- To demonstrate the effects of CNP520 vs placebo on function. □

- To demonstrate the effects of CNP520 vs placebo on Magnetic Resonance Imaging (MRI) measures suggestive of cerebral amyloid angiopathy (CAA). □

- To demonstrate the effects of CNP520 vs placebo on brain atrophy. □

- To demonstrate the effects of CNP520 vs placebo on AD-related biomarkers.

0

Screening part I: Participants eligible for inclusion must fulfill all of the □
following criteria prior to scheduling the genetic disclosure. □

1. Written informed consent must be obtained before any assessment is □
performed as part of the study, including consent to receive disclosure of □
their risk estimates to develop clinical symptoms of AD based on their □
APOE genotype and, if HTs, with evidence of elevated brain amyloid. □

2. Male or female, age 60-75 years inclusive, at the time of signing the □
informed consent. To ensure that no more than 20% of participants in the age group 60-64 years are
randomized across the whole recruitment □
period, a site level process will be implemented. □

3. Females must be considered post-menopausal and not of child bearing □
potential i.e. they have had 12 months of natural (spontaneous) □
amenorrhea with an appropriate clinical profile (e.g. history of □
vasomotor symptoms), or have had surgical bilateral oophorectomy □
(with or without hysterectomy), total hysterectomy, or tubal ligation. □

4. Intellectually, visually and auditorily capable, fluent in, and able to □
read, the language in which study assessments are administered (e.g. □
completion of at least 6 years of regular schooling or sustained □
employment or equivalent local level of knowledge). □

5. Mini-Mental State Examination total score ≥ 24 . □

6. Willing to have a study partner throughout the study. □

Screening part II: Participants eligible for inclusion must fulfill all of the □
following criteria prior to randomization based on the results from the □
screening test procedures. □

7. Carrier of at least one $\epsilon 4$ allele of the APOE gene: HMs with elevated □
or not elevated brain amyloid OR HTs with elevated brain amyloid (as □
measured in CSF collected via lumbar puncture or by amyloid PET □
imaging). □

Note: In cases where both lumbar puncture (CSF) amyloid and amyloid □
PET imaging tests are performed, at least one should be indicative of □
elevated brain amyloid. □

8. Cognitively unimpaired at screening visit as defined by: Score of 85 or □
greater on the RBANS delayed memory index score AND CDR global □
score of 0 with two special exceptions: a) If the RBANS delayed memory □
index score is between 70 and 84 (inclusive) AND the global CDR = 0, □
the participant may be allowed to continue ONLY if the investigator □
judges that cognition is unimpaired following review of the □

MCI/dementia criteria; b) If the global CDR score = 0.5 AND the RBANS delayed memory index score is 85 or greater, the participant may be allowed to continue ONLY if the investigator judges that cognition is unimpaired following review of the MCI/dementia criteria.

9. Having a study partner who agrees to participate in the study and who is intellectually, visually, and auditorily capable, and fluent in, and able to read, the language in which study assessments are administered. Additionally, the study partner must be capable of and willing to: a) Accompany the participant to visits that requires the input of the study partner; b) Meet the definition of a "study partner". Other protocol defined inclusion criteria may apply.

Screening part I: Participants will be excluded if they fulfill any of the following criteria prior to scheduling the genetic disclosure.

1. Current medical or neurological condition that might impact cognition or performance on cognitive assessments e.g. MCI, dementia, Huntington's or Parkinson's disease etc.
2. Advanced, severe progressive or unstable disease that may interfere with the safety, tolerability and study assessments, or put the participant at special risk e.g. active hepatitis, HIV infection, severe renal impairment, severe hepatic impairment etc.
3. History of malignancy of any organ system, treated or untreated, within the past 60 months, regardless of whether there is evidence of local recurrence or metastases. However, localized nonmalignant tumors not requiring systemic chemo- or radio-therapy, localized basal or squamous cell carcinoma of the skin, in-situ cervical cancer are permitted.
4. Current treatment with Cholinesterase Inhibitors and/or another AD treatment.
5. Clinically relevant depigmenting or hypopigmenting conditions or active/history of chronic urticaria in the past year.
6. Score "yes" on item 4 or 5 of the Suicidal Ideation section of the eCSSRS patient-reported outcome, if this ideation occurred in the past 6 months, or "yes" on any item of the Suicidal Behavior section, except for the "Non-Suicidal Self- Injurious Behavior", if this behavior occurred in the past 2 years prior to screening.
7. Lacking psychological readiness to receive APOE genotype/amyloid status results, as assessed based on investigator's judgement supported by the pre-disclosure rating scales: Geriatric Depression Scale total score >6; Six Item Subset Inventory of the modified State Trait Anxiety Inventory total score >17.
8. Use of other investigational drugs prior to screening until: Small molecules: after 5 half-lives, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; Biologicals: blood concentration has returned to baseline (or below serological responder threshold) for antibodies induced by active immunotherapy; or 5 half-lives for monoclonal antibodies or other biologicals.
9. Treatment
 - a) in the 4 weeks prior to randomization with any drug or treatment known for the potential to cause major organ system toxicity i.e. drugs that may require periodic safety monitoring of a specific organ or body fluid.

b) in the 4 weeks prior to randomization and/or current treatment with any CNS active drugs with the exceptions.

10. Current chronic treatment (>3 months) with: Strong CYP3A4 inducers or inhibitors; Drugs with a narrow therapeutic index known to be primarily metabolized by CYP2C or CYP3A isoenzymes and sensitive P-gp substrates.

11. Violations of concomitant medication restrictions.

12. Donation or loss of 400 mL or more of blood within 8 weeks prior to screening blood sampling and/or lumbar puncture if applicable.

13. Contraindication or intolerance to MRI investigations.

Screening part II: Participants fulfilling any of the following criteria based on results from the screening test procedures will be excluded.

14. A positive drug screen, if, in the investigator's opinion, this is due to drug abuse. Participants with a positive drug screen not believed to be related to drug abuse can be re-screened.

15. Previous participation in a CNP520 study with >3-month exposure to active treatment.

16. Significantly abnormal laboratory results at screening, meeting the exclusionary alert values specified in the Laboratory Manual. If, in the opinion of the investigator, an abnormal finding is the result of a temporary condition, the laboratory test can be repeated.

17. Current significant ECG findings from central reader that are assessed as clinically significant by the investigator. QTc interval >500 ms is exclusionary.

18. Brain MRI results from the central reading showing findings unrelated to AD that, in the opinion of the investigator might be a leading cause of future cognitive decline, might pose a risk to the participant, or might confound MRI assessment for safety monitoring (e.g. extensive white matter lesions, stroke, cerebrovascular disease as evidenced by multiple lacunar infarcts ≤ 20 mm or single infarct >20 mm, evidence of cerebral contusion etc.).

19. If PET scans are scheduled for this participant: Total dosimetry above the acceptable exposure in the country when combining the previous or planned Nuclear Medicine Radiology exposure and the scheduled study PET scan(s).

20. If CSF sampling is scheduled for this participant: Contraindication to lumbar puncture e.g. low platelet count, abnormal prothrombin time international normalized ratio, history of back surgery (except microdiscectomy or laminectomy over one level), signs or symptoms of intracranial pressure etc.

Other protocol defined exclusion criteria may apply.

- Time to the first event with event defined as the first confirmed diagnosis of MCI due to AD or dementia due to AD.
- Change from baseline to month 60 in APCC score.

- Baseline to month 60.
- Baseline to month 60.

- Change from baseline to month 60 in Clinical Dementia Rating Scale - Sum of Boxes (CDRSOB) score.□
- Frequencies, changes from baseline, Kaplan-Meier estimates when applicable of: Adverse events; Skin events based on a centralized dermatological monitoring; Safety findings from brain structural MRI central reader; Laboratory tests; Vital signs; ECG findings; Prospective suicidality assessment (ideation and behavior) from eC-SSRS.□
- Change from baseline to month 60 in total RBANS score and individual neurocognitive domain index scores.□
- Change from baseline to month 60 in total score of the Everyday Cognitive (ECog) scale: ECogsubject and ECog-informant.□
- Number, intensity and location of microhemorrhages and white matter hyperintensities using the Wahlund scale, both as assessed by central MRI reader.□
- Change from baseline to month 60 on volume of brain regions as measured by volumetric MRI.□
- Change from baseline to 24 and 60 months on: amyloid deposition as measured by standardized uptake ratio (SUVR) of radiotracer positron emission tomography (PET) scan; CSF levels of Aβ40, Aβ42; neurodegeneration as measured by CSF levels of total tau and□
- phosphorylated tau. Collected only in participants who consented to additional voluntary procedures.

- Baseline to month 60.□
- Baseline to month 60.□
- Baseline to month 60.□
- Baseline to month 60.□
- Baseline to month 60.□
- Baseline to month 60.□
- Baseline to month 24 and 60.

0

0

0

1

1

1

1

0

1

1

1

0

0

0

0

0

0

1

1

0

1

1

0

0

1

1

0

0

0

1

0

3

0

1

2

1

50

1

0

100000000325

13

100000000329

14

100000000337

11

100000000354

11

100000000361

13

100000000362

12

100000000394

11

100000000395

11

100000000403

12

100000000422

11

100000000429

13

100000000430

11

100000000432

11

100000000439

13

100000000465

12

100000000478

11

100000000501

11

100000000522

12

100000000527

12

100000000529

12

100000000536

12

100000000538

12

100000000556

11

100000000557

12

129

1

LVLS

6

11

7

6

2017-12-11

2017-08-03

0

0

0

0

0

0

0

1

400

1

1600

1

1

0

1

1

0

0

0

0

0

0

1

Participants at risk for the onset of clinical symptoms of AD

30

708

2000

Upon study completion (assuming futility was not met), participants may have the opportunity to enter an extension under a separate study, if eligible.

Cronenburg 2

Amsterdam

1081GN

100000000478

11

na

na

5.1.2.e

5.1.2.e

999999000397

1

5.1.2.e

Brain Research Center Den Bosch

Statenlaan 37

's Hertogenbosch

5223 LA

100000000478

11

5.1.2.e

5.1.2.e

999999000397

1

5.1.2.e

5.1.1.c

5.1.2.e

5.1.1.e

5.1.1.e

5.1.1.e

100000000536

12

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0
1
1
0

0

1

0

0

0

0

1

Receipt of batch samples from centres/shipment to reference labs; sample analysis; lab supplies

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000395

11

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0

1

0

0

0

0

1

0

0

0

1

Assay validation/transfer; sample analysis

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000557

12

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0
0
0
0
0
0
0
0
1
0

0

1

Central reading re: ECG; eCSSRS

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000557

12

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0

0

0

0

0

0

0

0

1

0

1

scans Site training; CRF/data review; central reading/image analysis/archiving of MRI and Tau PET

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000557

12

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0

0

0

0

0

0

0

0

1

0

1

Central dermatology, photography, monitoring & review; training

5.1.1.e

5.1.2.e

5.1.1.e

5.1.1.e

5.1.1.e

100000000557

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0
0
0
0
0
0
0
0
0
0
0
1

Supply of Amyloid PET ligand (flutemetamol) to various sites in various countries

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000557

12

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0

0

0

0

0

0

0

0

1

0

1

training Amyloid/Tau biomarker supply/expertise; PET reading/analysis/archiving; CRF/data review;

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000557

12

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0

0

0

0

0

0

0

0

0

0

1

Training; reading/archiving re:scales/MCI&AD diagnosis; adjudication;eSource data collection

Parexel International GmbH

CTRS-PL

Klinikum Westend, Haus 18, Spandauer Damm 130

Berlin

D-14050

100000000403

12

5.1.2.e [REDACTED]@parexel.com

+49 30 [REDACTED] 5.1.2.e

+49-30 [REDACTED] 5.1.2.e

5.1.2.e

5.1.2.e

0

0

1

0

0

0

0

0

0

0

0

0

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000556

11

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0

0

0

0

0

0

0

0

0

0

0

1

Regional warehousing/auxiliary labelling

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000557

12

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0

0

0

0

0

0

0

0

0

0

0

1

Regional warehousing/auxiliary labelling

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000522

12

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0
0
0
0
0
0
0
0
0
0
0
0

1

Regional warehousing/auiliary labelling

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000536

12

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0

0

0

0

1

0

0

0

0

0

0

1

Subject randomization management; Drug supply management; IRT services

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000557

12

5.1.2.e

0

0

0

0

0

0

0

0

0

0

0

1

Long term Sample storage and shipments

5.1.1.c

5.1.2.e

5.1.1.c

5.1.1.c

5.1.1.c

100000000557

12

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0

0

0

0

0

0

0

0

0

0

0

1

liaison Protocol, analysis plan & IDMC review; SAE programming & SAE narratives; IDMC reports &

5.1.1.e

5.1.1.e

5.1.1.e

5.1.1.e

100000000536

12

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0

0

0

0

0

0

0

0

0

0

0

1

5.1.1.c

; Data collection and management

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000557

12

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

0
0
0
0
0
0
0
0
0
0
0
0
1

Implementation and management of study website; Management of site recruitment tools;
Travel support

5.1.1.c

5.1.1.c

5.1.1.c

5.1.1.c

100000000478

11

0
0
0
0
0
0
0
0
0
0
0
0
1

Rental of -70 freezer to BRC Den Bosch

Central Committee on Research Involving Human Subjects (CCMO)

Parnassusplein 5

The Hague

2511 VX

100000000478

11

2017-09-27

999999000124

1

999999000406

1

2017-10-10

METc VUmc

van der Boechorststraat 7

Amsterdam

1081 BT

100000000478

11

2017-09-19

999999000000

1

999999000406

1

2018-07-06

Validate Application Results

EudraCT Number:	2016-002976-28
Sponsor's Protocol Code Number:	CCNP520A2202J
National Competent Authority:	Netherlands - Competent Authority
Validation Date and Time:	2019-02-05 09:52:26 GMT

The Clinical Trial (EEA CTA) has passed all validation rules.

Substantial Amendment Notification Form (Cf. Section 3.7.b of the *Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial*¹)

NOTIFICATION OF A SUBSTANTIAL AMENDMENT TO A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE EUROPEAN UNION

For official use:

Date of receiving the request :	Grounds for non acceptance/ negative opinion : ☐ Date :
Date of start of procedure:	Authorisation/ positive opinion ☐ Date :
Competent authority registration number of the trial: Ethics committee registration number of the trial :	Withdrawal of amendment application ☐ Date :

To be filled in by the applicant:

This form is to be used both for a request to the Competent Authority for authorisation of a **substantial** amendment and to an Ethics Committee for its opinion on a **substantial** amendment. Please indicate the relevant purpose in Section A.

A TYPE OF NOTIFICATION

A.1 Member State in which the substantial amendment is being submitted:	The Netherlands
A.2 Notification for authorisation to the competent authority:	☐
A.3 Notification for an opinion to the ethics committee:	☐

B TRIAL IDENTIFICATION (*When the amendment concerns more than one trial, repeat this form as necessary.*)

B.1 Does the substantial amendment concern several trials involving the same IMP? ² yes ☐ no ☐
B.1.1 If yes repeat this section as necessary.

B.2 Eudract number: 2016-002976-28
B.3 Full title of the trial: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)
B.4 Sponsor's protocol code number, version, and date: CCNP520A2202J version 02, dated 18-December-2018

C IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST

C.1 Sponsor	
C.1.1 Organisation:	Novartis Pharma AG
C.1.2 Name of person to contact:	5.1.2.e
C.1.3 Address :	Lichtstrasse 35, 4056 Basel, Switzerland
C.1.4 Telephone number :	+41 5.1.2.e
C.1.5 Fax number :	
C.1.6 e-mail:	5.1.2.e @novartis.com

C.2 Legal representative³ of the sponsor in the European Union for the purpose of this trial (if different from the sponsor)	
C.2.1 Organisation:	Novartis Pharma Arzneimittel GmbH
C.2.2 Name of person to contact:	5.1.2.e
C.2.3 Address :	Roonstrasse 25, 90429 Nuernberg, Germany
C.2.4 Telephone number :	+49 5.1.2.e
C.2.5 Fax number :	+49 5.1.2.e
C.2.6 e-mail:	5.1.2.e @novartis.com

¹ OJ, C82, 30.3.2010, p. 1; hereinafter referred to as 'detailed guidance CT-1'.

² Cf. Section 3.7. of the detailed guidance CT-1.

³ As stated in Article 19 of Directive 2001/20/EC.

D APPLICANT IDENTIFICATION (please tick the appropriate box)

D.1 Request for the competent authority	
D.1.1 Sponsor	☐
D.1.2 Legal representative of the sponsor	☐
D.1.3 Person or organisation authorised by the sponsor to make the application	☐
D.1.4 Complete below:	
D.1.4.1 Organisation:	PAREXEL International Romania s.r.l.
D.1.4.2 Name of person to contact :	5.1.2.e
D.1.4.3 Address :	Metropolis Center, Str. Grigore Alexandrescu, No. 89-97, Bucharest, 010624, Romania
D.1.4.4 Telephone number :	+40 31 5.1.2.e
D.1.4.5 Fax number :	+40 37 5.1.2.e
D.1.4.6 E-mail:	5.1.2.e @Novartis.com

D.2 Request for the Ethics Committee	
D.2.1 Sponsor	☐
D.2.2 Legal representative of the sponsor	☐
D.2.1 Person or organisation authorised by the sponsor to make the application.	☐
D.2.2 Investigator in charge of the application if applicable ⁴ :	
• Co-ordinating investigator (for multicentre trial)	☐
• Principal investigator (for single centre trial):	☐
D.2.3 Complete below	
D.2.3.1 Organisation :	
D.2.3.2 Name :	
D.2.3.3 Address :	
D.2.3.4 Telephone number :	
D.2.3.5 Fax number :	
E-mail :	

E SUBSTANTIAL AMENDMENT IDENTIFICATION

E.1 Sponsor's substantial amendment code number, version, date for the clinical trial concerned:
CCNP520A2202J Protocol Amendment version 02, dated 18-December-2018, Subject leaflet inclusive ICF main study BRC Amsterdam version 3.0 dated 15Jan2019, Subject leaflet inclusive ICF main study BRC Den Bosch version 3.0 dated 15Jan2019, Information leaflet for study partner subject version 2.0 dated 15Jan2019 and Information leaflet summary main study version 2.0 dated 15Jan2019.

E.2 Type of substantial amendment	
E.2.1 Amendment to information in the CT application form	yes ☐ no ☐
E.2.2 Amendment to the protocol	yes ☐ no ☐
E.2.3 Amendment to other documents appended to the initial application form	yes ☐ no ☐
E.2.3.1 If yes specify:	
E.2.4 Amendment to other documents or information:	yes ☐ no ☐
E.2.4.1 If yes specify: Informed Consent Form	
E.2.5 This amendment concerns mainly urgent safety measures already implemented ⁵	yes ☐ no ☐
E.2.6 This amendment is to notify a temporary halt of the trial ⁶	yes ☐ no ☐
E.2.7 This amendment is to request the restart of the trial ⁷	yes ☐ no ☐

⁴ According to national legislation.

⁵ Cf. Section 3.9. of the detailed guidance CT-1.

⁶ Cf. Section 3.10. of the detailed guidance CT-1.

⁷ Cf. Section 3.10. of the detailed guidance CT-1.

E.3	Reasons for the substantial amendment:	
E.3.1	Changes in safety or integrity of trial subjects	yes ☐ no ☐
E.3.2	Changes in interpretation of scientific documents/value of the trial	yes ☐ no ☐
E.3.3	Changes in quality of IMP(s)	yes ☐ no ☐
E.3.4	Changes in conduct or management of the trial	yes ☐ no ☐
E.3.5	Change or addition of principal investigator(s), co-ordinating investigator	yes ☐ no ☐
E.3.6	Change/addition of site(s)	yes ☐ no ☐
E.3.7	Other change	yes ☐ no ☐
E.3.7.1	If yes, specify: <u>Protocol amendment:</u> Protocol v02: The main purpose of this amendment is to implement additional monitoring of cognition and neuropsychiatric signs and symptoms for participants and inform participants about the recent findings from other BACE-inhibitors that was implemented following an urgent safety measure (USM). ICF: The protocol changes affect the informed Consent, and a revised Informed Consent Form (ICF) takes into account the changes described in the protocol amendment.	
E.3.8	Other case	yes ☐ no ☐
E.3.8.1	If yes, specify	

E.4	Information on temporary halt of trial⁸	
E.4.1	Date of temporary halt (YYYY/MM/DD)	
E.4.2	Recruitment has been stopped	yes ☐ no ☐
E.4.3	Treatment has been stopped	yes ☐ no ☐
E.4.4	Number of patients still receiving treatment at time of the temporary halt in the MS concerned by the amendment ()	
E.4.5	Briefly describe (free text): - Justification for a temporary halt of the trial - The proposed management of patients receiving treatment at time of the halt (<i>free text</i>). The consequences of the temporary halt for the evaluation of the results and for overall risk benefit assessment of the investigational medicinal product (<i>free text</i>).	

F DESCRIPTION OF EACH SUBSTANTIAL AMENDMENT⁹ (*free text*):

Previous and new wording in track change modus	New wording	Comments/explanation/reasons for substantial amendment
As described in the CCNP520A2202J Protocol amendment version 02, track changes version, available upon request	As described in the CCNP520A2202J Protocol amendment version 02, clean versio, available upon request	This amendment addresses proactive actions required to enhance the ongoing monitoring of CNP520. The changes to the protocol are required to reflect the Urgent Safety Measure (USM) action plan from 13-November-2018. Other changes include change in dose adaptation strategy by introducing a lower dose regimen (LDR). The decision to introduce the option for DRM and to remove the original potential for adaptation was not driven by data of the clinical trial, but on other sponsor's BACE inhibitor results. In addition, the DRM will keep main design features unchanged including the statistical testing procedure. Changes to specific sections of the

⁸ Cf. Section 3.10. of the detailed guidance CT-1.

⁹ Cf. Section 3.7.c. of the detailed guidance CT-1. The sponsor may submit this documentation on a separate sheet.

		protocol are described in track changes version, available upon request
--	--	---

The protocol changes herein affect the Informed Consent, and a revised Informed Consent takes into account the changes described in the protocol amendment. The updated ICF version will be used to re-consent participants already enrolled in the trial and be used for consenting any newly enrolled participant.

G CHANGE OF CLINICAL TRIAL SITE(S)/INVESTIGATOR(S) IN THE MEMBER STATE CONCERNED BY THIS AMENDMENT

G.1 Type of change G.1.1 Addition of a new site G.1.1.1 Principal investigator (provide details below) G.1.1.1.1 Given name G.1.1.1.2 Middle name (if applicable) G.1.1.1.3 Family name G.1.1.1.4 Qualifications (MD.....) G.1.1.1.5 Professional address G.1.2 Removal of an existing site G.1.2.1 Principal investigator (provide details below) G.1.2.1.1 Given name G.1.2.1.2 Middle name (if applicable) G.1.2.1.3 Family name G.1.2.1.4 Qualifications (MD.....) G.1.2.1.5 Professional address G.1.3 Change of co-ordinating investigator (provide details below of the new coordinating investigator) G.1.3.1 Given name G.1.3.2 Middle name G.1.3.3 Family name G.1.3.4 Qualification (MD.....) G.1.3.5 Professional address G.1.3.6 Indicate the name of the previous co-ordinating investigator: G.1.4 Change of principal investigator at an existing site (provide details below of the new principal investigator) G.1.4.1 Given name G.1.4.2 Middle name G.1.4.3 Family name G.1.4.4 Qualifications (MD.....) G.1.4.5 Professional address G.1.4.6 Indicate the name of the previous principal investigator:
--

H CHANGE OF INSTRUCTIONS TO CA FOR FEEDBACK TO SPONSOR

H.1 Change of e-mail contact for feedback on application*	
H.2 Change to request to receive an .xml copy of CTA data	☐ yes ☐ no
H.2.1 Do you want a .xml file copy of the CTA form data saved on EudraCT?	☐ yes ☐ no
H.2.1.1 If yes provide the e-mail address(es) to which it should be sent (up to 5 addresses):	
H.2.2 Do you want to receive this via password protected link(s) ¹⁰ ?	☐ yes ☐ no
If you answer no to question H.2.2 the .xml file will be transmitted by less secure e-mail link(s)	
H.2.3 Do you want to stop messages to an email for which they were previously requested?	☐ yes ☐ no
H.2.3.1 If yes provide the e-mail address(es) to which feedback should no longer be sent:	
(*This will only come into effect from the time at which the request is processed in EudraCT).	

¹⁰ This requires a EudraLink account. (See <https://eudract.ema.europa.eu/> for details)

I LIST OF THE DOCUMENTS APPENDED TO THE NOTIFICATION FORM (cf. Section 3.7 of detailed guidance CT-1)

Please submit only relevant documents and/or when applicable make clear references to the ones already submitted. Make clear references to any changes of separate pages and submit old and new texts. Tick the appropriate box(es).

I.1 Cover letter	☐
I.2 Extract from the amended document in accordance with Section 3.7.c. of detailed guidance CT-1 (if not contained in Part F of this form)	☐
I.3 Entire new version of the document¹¹	EC ☐ CA ☐
I.4 Supporting information	EC ☐ CA ☐
I.5 Revised .xml file and copy of initial application form with amended data highlighted	☐
I.6 Comments on any novel aspect of the amendment if any:	

J SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

J.1	I hereby confirm that / confirm on behalf of the sponsor that (delete which is not applicable) • The above information given on this request is correct; • The trial will be conducted according to the protocol, national regulation and the principles of good clinical practice; and • It is reasonable for the proposed amendment to be undertaken.
------------	---

J.2 APPLICANT OF THE REQUEST FOR THE COMPETENT AUTHORITY (as stated in section D.1): ☐	
J.2.1	Signature ¹² :
5.1.2.e	
J.2.2	Print name : 5.1.2.e on behalf of 5.1.2.e
J.2.3	Date : 07-Feb-2019

J.3 APPLICANT OF THE REQUEST FOR THE ETHICS COMMITTEE (as stated in section D.2): ☐	
J.3.1	Signature ¹³ :
J.3.2	Print name:
J.3.3	Date :

¹¹ Cf. Section 3.7.c. of the detailed guidance CT-1.

¹² On an application to the Competent Authority only, the applicant to the Competent Authority needs to sign.

¹³ On an application to the Ethics Committee only, the applicant to the Ethics Committee needs to sign.

PAREXEL International Romania s.r.l.

Metropolis Center - Str. Grigore Alexandrescu, Nr.89-97, Sector 1, 010624 Bucharest, Romania
J40/9291 /2004; CUI: RO 16494261

Phone: +4031 5.1.2.e / Fax: +4031 5.1.2.e / www.PAREXEL.com

PER E-MAIL TO BI@CCMO.NL

CCMO

Attn. Competent Authority

Parnassusplein 5

2511 VX Den Haag

The Netherlands

07-Feb-2019

Subject: Digital Submission of a Substantial Amendment for approval:
- Protocol Amendment version 02 dated 18-December -2018

ToetsingOnline NL61015.029.17

Dossier no:

EudraCT no.: 2016-002976-28

Protocol code: CCNP520A2202J

Protocol title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)

Sponsor: Novartis Pharma AG, Lichtstrasse 35, Basel, 4056, Switzerland

EU Legal Rep: Novartis Pharma Arzneimittel GmbH, Roonstrasse 25, Nürnberg, 90429, Germany

Dear Madam/Sir,

On behalf of the Sponsor, Novartis Pharma AG, PAREXEL International Romania s.r.l. herewith submits a substantial amendment to the above referenced clinical trial for review and authorization.

The changes in this amendment relate to:

- ☐ the addition of a new IMP;
- ☐ a substantial change of the current IMP
- ☒ other, namely: **Protocol:** Clinical Trial Protocol Amendment 02 dated 18 December 2018

The reasons for these changes are described in Section F of the enclosed Annex 2 form.

Protocol: Clinical Trial Protocol Amendment 02 dated 18 December 2018:

This amendment primarily addresses proactive actions required to enhance the ongoing monitoring of CNP520. The changes to the protocol are required to reflect the Urgent Safety Measure (USM) action plan from 13Nov2018. Other changes to the protocol include change in dose adaptation strategy by introducing a lower dose regimen option, incorporation of changes required by local health authorities and clarifications of different administrative aspects of the protocol.

PAREXEL International Romania s.r.l.

Metropolis Center - Str. Grigore Alexandrescu, Nr.89-97, Sector 1, 010624 Bucharest, Romania

J40/9291 /2004; CUI: RO 16494261

Phone: +4031 5.1.2.e / Fax: +4031 5.1.2.e / www.PAREXEL.com

The USM was triggered by the data disclosed about two other BACE inhibitors indicating an increase in neuropsychiatric events along with a decline in cognition starting in the first 3 to 6 months of treatment. The protocol is therefore amended to include an additional cognitive assessment with RBANS at the 3 month visit, as well as the NPI-Q at 3 and 6 months and every 6 months thereafter.

Results from studies of two other compounds with the same mechanism of action did not indicate a decline in cognitive performance or increase in neuropsychiatric events, making it difficult to know whether the negative effects reported for some of the other compounds are due to BACE inhibition per se or due to other properties of the drugs. The available data from other sponsors indicate that the early effects on cognition were found with doses of BACE inhibitors leading to at least 60 % reduction of A β in CSF. The doses of CNP520 in this study, 50 mg and 15 mg, achieve 86% and 68% median reduction of CSF A β , respectively.

In light of the new data from some other BACE inhibitor compounds, potential lower dose regimen options targeting less than 60% reduction of CSF A β are being incorporated into the protocol. Such dose regimen modification (DRM process) could be activated upon DMC recommendation after review of CNP520 data and/or in light of new data on either CNP520 or other BACE inhibitors. While the protocol previously included an adaptive design allowing a dose reduction from the current 50 mg to 15 mg once daily dose, this amendment removes the original adaptation process since these two doses are deemed to be too close in terms of CSF A β lowering and replaces it with the DRM.

Summary/ list of changes made to the previous version are described in the pages 13-15 of the Protocol and are available upon request.

Changes to specific sections of the protocol are described in the track changes version of the protocol using strikethrough red font for deletions and red underlined for insertions.

Ensuing from this amendment the Informed Consent Form was updated.

Additional information:

This is to inform you that the potential future 6 mg dosage strength described in the protocol is not yet included to the IMPD and will be added shortly and provided to Health Authorities for approval.

The 6 mg Lower dose Regimen will not be implemented until approval

EudraCT Application Form

The sections A.4.2, A.4.3, E.3 and E.4 of the EudraCT application form were updated to be in line with this amendment with revised sections highlighted in the enclosed updated pdf-version.

PAREXEL International Romania s.r.l.

Metropolis Center - Str. Grigore Alexandrescu, Nr.89-97, Sector 1, 010624 Bucharest, Romania
J40/9291 /2004; CUI: RO 16494261

Phone: +4031 5.1.2.e / Fax: +4031 5.1.2.e / www.PAREXEL.com

Additional EudraCT application Form updates:

- ☐ The Sponsor contact person was changed, section B.1
- ☐ A typo was observed and corrected in section E.6.9
- ☐ Since the previous submission, updates have been made to the list of Participating Countries, section E.8.6.3; Sections D.2.4.1 were also updated
- ☐ Section E.8.10.2 was updated to reflect the current situation
- ☐ Section F.4.1 has been updated from 40 to 30 patients
- ☐ Vendor addition/ removal, Vendor information updates, section G.3 and G.5.

The EudraCT form was updated accordingly.

Please find the following study documents supporting this request for approval attached to this e-mail:

CCMO numbering	Document	Version /Date
A.	Letter	
A1	Cover Letter	07-Feb-2019
B	Forms	
B3a B3b B3c	Revised EudraCT Application Form ✓ PDF copy highlighted ✓ XML file ✓ Validation Report <i>XML File Identifier: Z/948hmPu/x1oBZr6E7cs//0vj0=</i>	05-Feb-2019
B5	Substantial Amendment Notification Form	07-Feb-2019

According to the regulatory requirements of the Netherlands, it is required to submit only the applicable EudraCT forms to support a substantial amendment submission.

Therefore, the following documents are not attached, but are available upon request:

CCMO numbering	Document	Version /Date
C	Protocol related	
C1a	Protocol CCNP520A2202J v2.0 Clean	V2.0/18-Dec-2018
C1b	Protocol CCNP520A2202J v2.0 Track changes	V2.0/18-Dec-2018

PAREXEL International Romania s.r.l.

Metropolis Center - Str. Grigore Alexandrescu, Nr.89-97, Sector 1, 010624 Bucharest, Romania
J40/9291 /2004; CUI: RO 16494261

Phone: +4031 5.1.2.e / Fax: +4031 5.1.2.e / www.PAREXEL.com

C1c	Protocol CCNP520A2202J Version 2.0 Sponsor Signature Page	20-Dec-2018
E.	Information for the research subject	
E1.E2a	Subject leaflet inclusive ICF main study BRC Amsterdam - Clean and Tracked changes	V3.0/15-Jan-2019
E.E2b	Subject leaflet inclusive ICF main study BRC Den Bosch - Clean and Tracked changes	V3.0/15-Jan-2019
E4a	Information leaflet for study partner subject - Clean and Tracked changes	V2.0/15-Jan-2019
E4b	Information leaflet summary main study - Clean and Tracked changes	V2.0/15-Jan-2019

With this submission, we declare that all relevant documents of the present submission dossier are signed by the persons authorised for this task.

We trust that the information provided in the application is sufficient, however if you require any further information, please contact us.

Yours faithfully,

PAREXEL International Romania SRL

5.1.2.e on behalf of 5.1.2.e
Metropolis Center, Str. Grigore Alexandrescu, No. 89-97
Bucharest, Sector 1, Romania, 010624

Tel : +4.031 5.1.2.e
Fax: +40 037 5.1.2.e
Email: 5.1.2.e [@Novartis.com](mailto:5.1.2.e@Novartis.com)

5.1.2.e